MATERIAL AND METHOD FOR STORING, TRANSFERRING AND DELIVERING MESENCHYMAL STEM CELLS THAT ARE IMMEDIATELY AVAILABLE AND FUNCTIONAL IN ASSOCIATION WITH A HERCIATE ATTACK

DE602018076985T2Active Publication Date: 2024-11-27SCHUSSLER OLIVIER
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
DE602018076985
Authority / Receiving Office
DE · DE
Patent Type
Patents
Current Assignee / Owner
Priority Date
2017-08-25
Filing Date
2018-06-11
Publication Date
2024-11-27
Estimated Expiration
2038-06-11

AI Technical Summary

Technical Problem

Current cell therapies for myocardial infarction face challenges such as low survival and engraftment of mesenchymal stem cells (MSCs), delayed logistical issues due to freezing and thawing, and loss of paracrine activity, which hinder effective regeneration and contractility improvement of infarcted myocardial tissue.

Method used

A method involving the differentiation of MSCs into contractile cells and their association with a 3D support to form a contractile tissue biomaterial, which is compatible with low-temperature storage and transfer, maintaining paracrine activity and immediate functionality, and is suitable for promoting myocardial regeneration and angiogenesis.

Benefits of technology

The approach enhances the retention and survival of MSCs at the treatment site, preserves paracrine activity, and improves myocardial contractility, offering a more effective and immediate therapeutic solution for myocardial infarction without the need for freezing, thus overcoming logistical and functional limitations of prior methods.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art

Description

DOMAINE TECHNIQUE

[0001] The application describes a method that involves differentiating mesenchymal stem cells (MSCs) into contractile cells and associating the differentiated cells with a 3D scaffold to obtain contractile tissue. Paracrine activity of the MSCs is induced during the process. The resulting biomaterials are compatible with the storage, transfer, and delivery of MSCs at low temperatures. The preparations are immediately available and functional.

[0002] The application describes a contractile cellular biomaterial, a production process for this biomaterial, and its medical applications. The biomaterial described is particularly well-suited for the preservation, angiogenesis, remodeling control, and regeneration of myocardial tissue, especially infarcted myocardial tissue. ARRIÈRE-PLAN TECHNOLOGIQUE

[0003] Myocardial tissue can suffer damage that reduces its contractility. This myocardial damage can lead to heart failure. It can have various origins, such as viral, genetic, or ischemic causes. The main cause of myocardial damage is myocardial infarction (heart attack). Myocardial infarction generally occurs due to the blockage of one or more coronary arteries, which deprives the myocardial tissue cells of their blood supply, and therefore their oxygen supply, leading to necrosis of one or more areas of the myocardium. Myocardial infarction is an extremely common condition in industrialized countries (1 in 500), occurring primarily in individuals over 50 years of age, with 25% of cases being severe.

[0004] Even when treated promptly within two hours, for example by reopening blocked arteries (angioplasty), a myocardial infarction generally leads to heart failure with a more or less significant loss of myocardial contractility. Secondary heart failure has a five-year mortality rate similar to that of cancer, at 50%.

[0005] The decrease in myocardial contractility is primarily due to the loss (through necrosis) of cardiac muscle cells. It is also due to a loss of myocardial extracellular matrix and a loss of supporting cells for this extracellular matrix, particularly cardiac fibroblasts. This extracellular matrix and these supporting cells are necessary for the regeneration of cardiac muscle cells, which are adherent cells. The loss of matrix and supporting cells therefore limits the regeneration capacity of cardiac muscle cells. Furthermore, it leads to ventricular remodeling, as the ventricle must adapt to the new blood pressure regime. The loss of cells and extracellular matrix is ​​also accompanied by an inflammatory response (initiated in particular by cell and matrix debris). During a myocardial infarction, these mechanisms are activated very rapidly.Cell necrosis, extracellular matrix fragments, and local cells will recruit inflammatory cells, initially neutrophils (PMNs) at 8 hours, then M1 macrophages after 24 hours. Under the influence of local myofibroblasts, M1 macrophages will transform into regenerative, angiogenic, and less detergent M2 macrophages. The accelerated presence of M2 macrophages improves recovery and preserves myocardial tissue. Myofibroblasts are increasingly recognized as key players in regulating the post-infarction response.

[0006] Post-infarction myocardial tissue is therefore ischemic and inflammatory tissue, which has undergone cellular loss and loss of extracellular matrix.

[0007] The human body is theoretically capable of a certain degree of recovery, or myocardial regeneration, controlled by myofibroblasts naturally generated by the differentiation of local fibroblasts or those originating from the bone marrow. However, this natural transformation is not immediate: the transformation of fibroblasts into myofibroblasts takes at least a week, and therefore these cells are not present in the acute phase. Furthermore, the inflammatory reaction that develops following a myocardial infarction tends to lead to ventricular remodeling and impaired ventricular contractility.

[0008] For the most advanced forms of heart failure, heart transplantation and / or mechanical ventilation remain possible treatments. The problem with these devices is that the best survival times are only a few years, they are very expensive, and there are many complications related to anticoagulation and impaired quality of life. Heart transplants are reserved for young patients because there is a critical shortage of donor organs. It is a very complex procedure with a 50% 10-year survival rate and numerous complications, including immunosuppressive treatments, secondary cancers, and organ rejection. etc. For heart attacks, which are an extremely common and serious condition, it is therefore necessary to find a treatment that is effective, inexpensive and can be used at all ages.

[0009] In cases of myocardial infarction with initial cardiogenic shock, there has been virtually no progress in the last 15 years, even with early revascularization, with 50% in-hospital mortality and 50% mortality for survivors in the first year.

[0010] Cell therapy has raised high hopes for improving outcomes in cases of myocardial infarction, but so far it has had limited clinical application because the results are too disappointing, even though some animal studies are promising. One explanation for the differences between clinical and animal studies could be the greater availability of cells due to logistical constraints in the context of myocardial infarction. In humans, there are no readily available preparations. Therapies are administered with a delay, and the cells are not used with optimal functionality.

[0011] Cell therapies have therefore been considered for the preservation, healing, or regeneration of myocardial tissue. Various cell types have been tested, including differentiated cells (e.g., cardiomyocytes) and stem cells (e.g., mesenchymal stem cells). All results with MSCs, although promising cells, show only a very small improvement in ventricular contractile function (less than 5%, whereas an improvement greater than 5% is needed for a survival benefit in patients). In animals, it has been shown that allogeneic MSCs administered immediately after myocardial infarction and modified with survival genes, such as AkT or Bcl2, can lead to improved systolic contractility. A correlation has also been demonstrated between the initial level of cell engraftment and recovery.The cells must be applied very early. One of the reported modes of action of MSCs. in vivo is the switch from initial cleansing cells (M1 macrophages) to regenerative angiogenic macrophages (M2 type). If MSCs are administered too late, their effect is diminished.

[0012] Differentiated cells, such as cardiomyocytes, present the problem of difficulty in obtaining sufficient quantities of adult cells. Consequently, research has increasingly focused on stem cells, such as mesenchymal stem cells.

[0013] In previous cell therapies, it is most often observed that there is insufficient survival of the administered cells, and that the level of engraftment of these cells on the infarcted area is very limited with loss of 90% after only 1 hour (a factor further aggravated if the myocardium contracts), so that the administered cells can migrate to sites that are unrelated to the area or tissue to be treated.

[0014] Collagen patches have been used to limit the migration of stem cells, particularly mesenchymal stem cells. Some of these patches have been able to limit ventricular remodeling, for example, by limiting diastolic distension, but these patches do not lead to an improvement in myocardial contractility, particularly systolic ventricular contractility ( cf. Simpson et al., 2007 Stem Cells 25(9): 2350-2357; more specifically Table 2 of this publication).

[0015] The problem of the survival, viability and engraftment of the administered cells is all the more delicate when the area to be treated is an ischemic and inflammatory area, that is to say not favorable to cell survival and viability.

[0016] The logistics of transferring cells require a minimum of 5-7 days for transport and delivery. Transferring cells at 37°C necessitates portable incubators, CO2 and oxygen, the ability to culture the cells upon arrival under cGMP conditions, and accredited facilities. Furthermore, MSCs are adherent cells that will either clump together or adhere to the walls of the transfer container. Delivering these cells is therefore technically challenging. At 37°C, cell metabolism is high. MSCs are multipotent cells that will differentiate uncontrollably. If the cells are stored at 37°C, there is no way to control this differentiation.In terms of metabolic demand, due to their contractile properties, contractile tissues, compared to non-contractile tissues at room temperature, are particularly demanding of nutrients and oxygen.

[0017] Prior art cell therapies generally utilize cells that are preserved by freezing. As cited in a study by Marquez-Curtis et al. (review Cryobiology. 2015 Oct;71(2):181-97), "the world of tissue engineering, gene therapy, regenerative medicine, and transplantation relies on the ability to preserve, store, and transport these cells." For logistical reasons with mesenchymal stem cells (MSCs), the question is not whether to freeze them, since there is no other solution, but how to preserve their functionality after freezing. Freezing is therefore considered essential with current techniques. Mesenchymal stem cells are present in small numbers in tissues and therefore must be amplified. in vitro In 2D culture, during the expansion phases, the cells are subcultured using enzymatic solutions. Once a sufficient batch of MSCs has been amplified, they are stored. A test batch for viral safety (possible genetic mutation) is then performed. Freezing also allows the MSCs to be maintained in a specific differentiation state (for storage and delivery to centers). After thawing, the cells will take several days to regain their functionality in culture (at least 72 hours). These MSCs are not immediately available in the context of a myocardial infarction and require expertise and accreditation from the center capable of re-expanding them. These skills limit the use of these cells.

[0018] These cells must therefore be thawed before being administered to the patient. The thawing process further delays the patient's therapeutic intervention. Moreover, regardless of the cryopreservation technique used, freezing and thawing reduces cell viability. For example, freezing and thawing mesenchymal stem cells is associated with high cell mortality, ultrastructural abnormalities, cell non-adherence for more than 24 hours, and a loss of paracrine immunosuppressive capacity for 48 to 72 hours after thawing. A loss of paracrine immunomodulatory activity has even been observed following thawing (Moll et al. 2014 Stem Cells 32(9): 2430-2442).In general, freezing and thawing adherent cells, whether mesenchymal stem cells or contractile cells, impairs their adhesion capacity or delays the return of their cell adhesion. Cell recovery requires culturing the cells in an incubator. Since thawed cells are not adherent, if injected with a support, they will not adhere to the support, and the initial cell loss would be very significant. Cell adhesion to the contractility support and engagement in contractility interactions (with increased and improved cell-cell and cell-support interactions) allows for better initial cell retention in the treatment area, unlike the injection of free cells, which results in the loss of 90% of cells after only one hour, and even more in a beating heart.The approach proposed in the application optimizes the performance of cell therapy through improved initial cell retention and better preservation of the cell population (improved initial retention, improved survival, and reduced secondary migration). It also allows cells to be applied in contact with, rather than within, the infarcted area, thereby preserving the pro-regenerative, immunosuppressive paracrine phenotype of the cells and maintaining their differentiation status.

[0019] One approach to delivering MSCs could be to culture them in 2D culture under hypothermia to slow their metabolism. However, at temperatures below 10°C in conventional serum culture media, 90% of MSCs or contractile cells are already dead after only 24 hours (Mathew et al., Tissue Eng. 2004;10(11-12):1662-1671). At low temperatures (>0°C), there are alterations in the ATP production cycle and degradation of membrane transporters (responsible for changes in ion balance with increased intracellular calcium, loss of intracellular potassium, and increased sodium, resulting in acidosis with a cytoplasmic pH of 4, normally 7). At low temperatures, the altered viscoelastic properties of membranes lead to more rigid membranes.A cascade of cell damage is triggered, involving the release of intracellular enzymes, activation of calcium-dependent phospholipase, activation of the cell death pathway via apoptosis, and destruction of the intracellular matrix involved in contractility (Baust et al., Organogenesis. 2009;5(3):90-96). Remarkably, in standard serum culture media, we are able to preserve cells for over a week without any loss of contractility.

[0020] Hypothermic solutions rich in lactobionate have been proposed to replace chloride and reduce its intracellular concentration, thereby limiting the oncotic pressure of lactobionate-sucrose-mannitol type solutions. These solutions are also buffered with Hepes.

[0021] Hypothermic solutions such as HYPERTHERMOSOL®< have been tested with cardiomyocyte progenitor cells. In these solutions, in addition to decreased survival over time, particularly after 4 days, and more than 50% mortality after 1 week (Van Burskirk et al., Bioprocess International. 2004:42-48), there is a very significant decrease in alpha-actinin after 48 hours (Herías, Cytotherapy, 16(4), S38). Furthermore, there is a very significant decrease in the CD9 marker (Ginis et al., Tissue Eng Part C Methods. 2012;18(6):453-463), which is a marker of fibroblasts. During the warming phases, the medium is toxic to the cells due to the release of free radicals. Therefore, the medium must be changed during warming, the cells centrifuged, and an incubator used to regenerate the cells. After warming, changing the medium and culturing in an incubator, it takes 24 to 48 hours for the surviving cells to produce beats (Snyder et al., 2005, Cell Preservation Technology, 3(1), 61-74.).

[0022] Therefore, these approaches do not allow for preparations to be stored for more than 5 days, whereas a minimum of 7 days is required for logistical reasons to transfer the preparations. If we imagine that these preparations will be used for a random event, additional storage capacity is needed, which the previous approaches do not allow even less.

[0023] The result is that in practice, specifically in clinical settings, cell therapies intended for the healing or regeneration of infarcted myocardial tissue have a low benefit / risk ratio.

[0024] The device as described is immediately available. There is no need to raise the temperature to 37°C. At room temperature, the device is contractile. The cells in the contractility supports can optionally be used with hypothermic solutions. In this case, since the cells are already adherent to the support, the cells and the support can be washed away by simply changing the medium. In the contractility support, the interactions between the cells themselves and between the cells and the support lead to physiological activation of the AKt survival gene, and stress proteins are reduced. This could explain the resistance of the cells in this structure under hypothermia.

[0025] The methods of regenerative (or scarring) therapy of myocardial tissue, particularly infarcted myocardial tissue, as described, offer advantages over prior art methods, notably the advantage of not requiring the frozen preservation of cells intended for administration to the patient or subject. These methods can, in particular, not only limit or even prevent myocardial remodeling, but also improve myocardial contractility.

[0026] Furthermore, we are also familiar with the document "Stiffness-controlled three-dimensional collagen scaffoids for differentiation of human Wharton's jelly mesenchymal stem cells into cardiac progenitor cells" (Yun-Li Lin et al., 2016), which describes the fabrication of stiffness-controlled 3D collagen scaffoids that allow the proliferation and differentiation of mesenchymal stem cells into cardiac progenitor cells on the surface of the scaffold. We are also familiar with the document " The effect of matrix stiffness on the differentiation of mesenchymal stem cells in response to TGF-β (Park et al., 2011) reveals the effect of matrix stiffness on the differentiation of mesenchymal stem cells in response to TGF-β1, and on the surface of the matrix. Finally, the document is also known. "Human mesenchymal stem cells cultured on silk hydrogels with variable stiffness and growth factor differentiate into mature smooth muscle cell phenotype" (Floren et al;, 2016) which reveals the effect of the elasticity of a porous fibroin hydrogel on the differentiation of mesenchymal stem cells in response to TGFβ1. However, these documents do not describe a contractile cellular biomaterial. RÉSUMÉ

[0027] The invention is stated in all of the attached claims.

[0028] In addition, this application describes a biomaterial, a process for producing this biomaterial, and medical applications of this biomaterial.

[0029] The biomaterial as described is contractile, and its contractility is spontaneous or induced. Furthermore, it may exhibit inducible paracrine activity (notably paracrine T-cell immunosuppressive activity).

[0030] The biomaterial as described in the application is particularly suitable for the repair (or healing) of myocardial tissue, especially infarcted myocardial tissue.

[0031] The biomaterial described in the application can, in particular, promote myocardial regeneration and / or angiogenesis in the infarcted area. The biomaterial described in the application can reduce the size of the infarcted area and / or limit or even prevent ventricular remodeling.

[0032] Most notably, the biomaterial as described in the application may lead to a lesser decrease or improvement in myocardial contractility.

[0033] The biomaterial as described in the application does not need to be frozen for preservation: it can be stored at a temperature above 0°C without losing its contractility properties (and possibly paracrine activity).

[0034] The biomaterial as described in the application comprises a three-dimensional, elastically compliant support that promotes the survival and differentiation of stem cells into contractile cells and enables the formation of contractile tissue. The support may be solid, and cell colonization of the support may be promoted by a porous structure.

[0035] Contractile tissue is formed by the differentiation of stem cells, particularly mesenchymal stem cells. Mesenchymal stem cells in demand also include preparations containing MSCs, such as cardiosphere-like "clusters" prepared from cardiac tissue fragments and enriched with progenitors for CKIT+ and MSCs.

[0036] Contractile tissue may, for example, comprise or be composed of cells selected from myofibroblasts, fibroblasts, myocytes, cardiomyocytes and muscle cells (including mixtures of two, three, four or five of these cell types) and progenitors for these cells and cells capable of differentiating into these cells.

[0037] The differentiation of stem cells, particularly mesenchymal stem cells, can involve exposing these cells to at least one agent selected from TGFβ (including TGFβ1), CTGF, EGF, and NUX1, mechanical stress, or electrical stimulation. Paracrine activity of contractile tissue can be induced by exposing cells of this tissue to at least one agent selected from IFNγ, TNFα, and IL1β, and / or by applying transient hypoxia to these cells.

[0038] The support (optionally solid and porous) can exhibit an elastic compliance of 0.1 to 30 kPa⁻¹. For example, cell-free contractility supports can have an elastic compliance of 0.4 kPa⁻¹ and 1.5 kPa⁻¹ after cell colonization. BRÈVE DESCRIPTION DES FIGURES

[0039] There Figure 1 shows an electron microscope observation of a biomaterial of demand (crosslinked collagen matrix as a porous solid support and differentiated MSCs by contact with platelet lysate; cf. (Example 1 below). The drawn rectangles delineate identifiable areas of contractile filament proteins. The arrows show regular interruptions of these filaments by dense bodies or possibly sarcomeres. The biomaterial has thus organized itself into a contractile structure. To our knowledge, stress bands and terminal organization of the contractile apparatus have never been demonstrated with MSCs placed in standard 2D culture. Figure 2 illustrates the contractility result exhibited by a biomaterial of demand (DHT-crosslinked collagen matrix; MSCs differentiated into myofibroblasts at least 80%). The contraction and relaxation kinetics are close to those of placental tissue ( cf. (Example 2 below). The Figures 3A et 3B illustrate that the demand-side relaxation property of a biomaterial is indeed an active phenomenon, and not a passive one (relaxation with elongation [top curves in Figure 3A et 3B ] and with a decrease in the force developed [bottom curves in Figures 3A et 3B]). Figure 3A ; case of a biomaterial with a DHT-crosslinked collagen matrix and with RGD peptide molecules, under electrical stimulation in tetanus and with inhibition of relaxation by RISORDAN. Figure 3B Case of a biomaterial with a DHT-crosslinked collagen matrix, stimulated by 0.05 M KCl, and inhibited by BDM (cf. (Example 2 below). The Figure 4 shows that a Hill curve could be established for a biomaterial of the demand (biomaterial with a DHT-crosslinked collagen matrix, and stored at a temperature above 0°C - in this case approximately 4°C). The Hill curve (hyperbola) is specific to contractile tissues (abscissa: tension (mN); ordinate: velocity Lo / s (10 -3 < ); cf. (Example 2 below). The Figure 5 shows the migration of cells from the cardiospheres into the substrates (change vs. IICSps (log scale)), the cells do not remain in cluster form (cf. g) but migrate and spread throughout the medium (cf. h) An induction of cardiac markers and a decrease in the stress proteins Hsp70, Hsp72, and Hsp90 was observed. Akt activation was also observed in MSC cells. DESCRIPTION DÉTAILLÉE

[0040] The invention is described in the attached set of claims and relates to a method for producing a contractile cellular biomaterial, which comprises the following steps: placing mesenchymal stem cells inside a three-dimensional support, said support having pores allowing the diffusion of nutrients and cell colonization in vitro and in vivo, inducing the differentiation of multipotent mesenchymal stem cells into contractile cells, chosen from myofibroblasts, myocytes, cardiomyocytes, or striated muscle cells, in a three-dimensional support with elastic compliance which allows the formation of contractile tissue by bringing said mesenchymal stem cells into contact with a differentiation-promoting agent chosen from TGFbeta, CTGF, EGF, NUX1 and platelet lysate, and inducing paracrine activity of said contractile cells, the induced paracrine activity further comprising T-cell immunosuppressive activity and / or indoleamine 2,3-dioxygenase (IDO) activation,said paracrine activity is induced by bringing these contractile cells into contact with at least one paracrine activity-inducing agent chosen from IFNgamma, TNFalpha and IL1beta, and / or the application of transient hypoxia to these contractile cells, . in which said three-dimensional support exhibits a cell-free elasticity compliance of 0.1 to 30kPa-1<, more particularly of 0.4 to 20 kPa-1<, more particularly of 0.5 to 15 kPa-1<, more particularly of 0.5 to 5 kPa-1<, said support containing the contractile cells thus produced is a contractile cellular biomaterial suitable for the regenerative therapy of myocardial tissue.

[0041] Furthermore, the present application describes a contractile biomaterial, more specifically a contractile cellular (bio)material.

[0042] This biomaterial is particularly suited to regenerative (or scarring) therapy of myocardial tissue, more specifically to regenerative (or scarring) therapy applied to ischemic and inflammatory myocardial tissue, and more specifically to myofibroblastic healing. post -heart attack.

[0043] The means of demand can include limit or even avoid ventricular remodeling; and / or decrease the size of the myocardial infarction or promote myocardial regeneration; and / or promote or increase angiogenesis at the level of the infarcted area.

[0044] Most notably, means of demand can lead to an improvement in myocardial contractility.

[0045] The biomaterial comprises cells and a support structure, which provides contractility. This support structure is three-dimensional. The support structure can be a solid, particularly a porous solid, and more specifically a three-dimensional porous solid.

[0046] The support in question may, for example, be a sponge (e.g., a DHT-crosslinked sponge) or a foam. The support itself may, for example, be a gel or a hydrogel.

[0047] The support can be associated with an agent.

[0048] The support can be physically stimulated

[0049] The support can be injectable or administered via a minimally invasive route. It can have shape memory. It can be produced by 3D printing. The support can be chemically, physically, or enzymatically crosslinked. The support can be oriented.

[0050] The substrate can, for example, be a collagen-based substrate (natural or synthetic collagen, purified or unpurified), possibly chemically modified by chemical treatment, heat, or gelatin treatment. The substrate can be modified with covalently bonded adhesion molecules.

[0051] The cells are obtained by differentiating stem cells. They form a cellular tissue and are present within the (porous) molecular structure of the (solid) substrate, that is, in the pores of the (porous solid) substrate. The substrate, more specifically the optionally porous solid substrate, can therefore be perceived as a 3D substrate (as opposed to classical cell culture, which is a 2D culture).

[0052] The biomaterial is contractile, meaning it has contraction and relaxation properties. Indeed, the cellular tissue produced by stem cell differentiation is contractile, and the (solid) (porous) support containing this cellular tissue exhibits a degree of elasticity that allows this contractility to be expressed.

[0053] The biomaterial (i.e., the cellular tissue it contains) also exhibits inducible paracrine activity. Inducible or induced paracrine activity includes, in particular, immunomodulatory activity, notably T-cell immunosuppression.

[0054] Remarkably, the biomaterial can be stored without freezing. In fact, it can be kept at a temperature above 0°C and retain its contractility properties. For example, it still exhibits contractility, and optionally inducible paracrine activity, after being stored for 5 days at a temperature above 0°C but below 10°C.

[0055] The biomaterial in question does not require freezing and, therefore, can be made available and functional very quickly: upon removal from its storage container, the biomaterial is immediately administrable or transplantable. The subject or patient can receive it without any waiting period for thawing, medium changes, or culture. It can even be used at room temperature, not necessarily at 37°C. Because the cells adhere to the support and the support has significant porosity, there is free diffusion of the media through the support, allowing for medium changes without the need for repeated centrifugations to recover cells from suspension.

[0056] When placed on ischemic and inflamed myocardial tissue, the biomaterial in question acts like a wound dressing. It promotes myocardial regeneration. It may also promote angiogenesis.

[0057] The biomaterial in question can limit or even prevent post-infarction ventricular remodeling. It can also reduce the size of the infarcted area. The biomaterial can potentially prepare the ventricle for cell therapy or other treatments aimed at addressing damaged myocardium. Several biomaterials can be used simultaneously or sequentially. Biomaterials can be stacked or used in a "sandwich" configuration. They can be applied to an extracardiac site before being applied either free-floating or as a vascularized graft to the infarcted area. One such site could be the peritoneal cavity, including the omentum and surrounding muscles. The biomaterial can be covered or protected on the myocardium by a device or, potentially, a pericardial patch.

[0058] Most notably, the biomaterial on demand can lead to preservation or improvement of myocardial contractility.

[0059] The application describes a production process for this biomaterial.

[0060] The application process includes inducing the differentiation of stem cells into contractile cells, more specifically into cells that form (among themselves) (and with the support) a contractile tissue.

[0061] The application process may involve inducing the differentiation of stem cells into contractile cells preferentially within a three-dimensional contractility scaffold that will facilitate this differentiation. This contractility scaffold, with a specific degree of elasticity, will allow the development of contractile tissue with the emergence of strength and shortening of the formed structure. This contractility may be spontaneous or induced. It may not be permanent. For contractile tissue to develop, it is important that the cells within the scaffold are contractile or have the capacity to become so. These contractile cells must be interconnected and connected to the scaffold. The monomers / polymers of the scaffold may be interconnected. The elasticity of the scaffold must not be zero; it must be compatible with deformation by the associated cell population.This is not an emulsion where the cellular and contractile elements are not connected and the elasticity compliance is zero. If the elasticity compliance is too high, cartilaginous bone tissue will be produced. If the elasticity compliance is too low, contractile tissue will not be obtained (and fibroblasts, for example, will not differentiate into myofibroblasts).

[0062] Stem cells can be multipotent and / or pluripotent stem cells, including adult (non-embryonic) stem cells, such as cardiac stem cells (CSCs), or mesenchymal stem cells, particularly mesenchymal stem cells. These are typically human cells. The cells may be genetically modified. Stem cells can be derived from the genetic reprogramming of differentiated cells. The cells may be induced pluripotent stem cells (iPSCs). Stem cells may be obtained from clinically usable cell banks. The cells may be produced in the form of cell clusters. The cells may be fused.

[0063] Mesenchymal stem cells are often derived from the mesoderm and also from a trans-differentiation of the endothelium or epithelium into the mesenchyme.

[0064] Stem cells, particularly mesenchymal stem cells, can be derived from any source that a person skilled in the art considers appropriate, for example, from adipose tissue, bone marrow, organ support tissue, bone, cartilage, or muscle, cardiac tissue and derivatives.

[0065] Stem cells, particularly mesenchymal stem cells, can be autologous or heterologous. Cells can be autologous or allogeneic.

[0066] They can come from unused human tissue or tissue discarded for another reason, as well as from tissue taken from a recently deceased person.

[0067] In this application, unless otherwise specified, or the context dictates otherwise, all terms have their usual meaning in the relevant field(s).

[0068] For example, the term "mesenchymal stem cells" ( Mesenchymal Stem Cells Or Mesenchymal Stromal Cells or MSC) generally refers to cells as defined in Dominici et al. 2006 (Cytotherapy 8(4): 315-317), that is, cells that adhere to plastic (after 24 hours of contact with the surface of the plastic in a culture dish, for example), that express CD105, CD73, and CD90, but do not express CD45, CD34, CD14 (or C11b), CD79a (or CD19), and HLA-DR. MSCs can also be characterized by their ability to differentiate into osteoblasts, adipocytes, and chondroblasts.

[0069] Inducing the differentiation of stem cells, particularly mesenchymal stem cells, into contractile cells, more specifically into cells forming contractile tissue, may include bringing the stem cells, particularly mesenchymal stem cells, into contact with at least one differentiation-promoting agent chosen from TGFbeta (Tumor Growth Factor beta) (more specifically at least TGFbeta1), CTGF ( Connective Tissue Growth Factor ), EGF ( Epidermal Growth Factor ) and RUNX1 ( Runt-related transcription factor 1 ), transcription regulators and mechanical stress, more particularly among TGFbeta, CTGF, EGF and RUNX1, more particularly with at least TGFbeta (more particularly with at least TGFbeta1), and more particularly with at least TGFbeta (more particularly with at least TGFbeta1) and optionally with at least one other differentiating agent selected from CTGF, EGF and RUNX1. The platelet lysate is a product which contains TGFbeta (more particularly TGFbeta1) and / or CTGF and / or EGF and / or RUNX1, more particularly with at least TGFbeta (and optionally CTGF and / or EGF and / or RUNX1), more particularly with at least TGFbeta1 (and optionally CTGF and / or EGF and / or RUNX1). Inducing the differentiation of stem cells, particularly mesenchymal stem cells, into cells forming contractile tissue may therefore involve bringing stem cells, particularly mesenchymal stem cells, into contact with (at least) platelet lysate.

[0070] Contractile cells (or the cells that form contractile tissue) can be differentiated cells, or a mixture of differentiated cells and stem cells (which mixture must include at least 50%, and in particular at least 80%, of differentiated cells).

[0071] Contractile cells (or the (differentiated) cells forming the contractile tissue) may include or be selected cells from among myofibroblasts, fibroblasts, myocytes, cardiomyocytes, and muscle cells (including mixtures of two, three, four, or five of these cell types), more specifically, selected cells from among myofibroblates and fibroblasts (including mixtures of myofibroblasts and fibroblasts). More specifically, the (differentiated) cells forming the contractile tissue may include or be myofibroblates.

[0072] More specifically, contractile cells (or the (differentiated) cells forming the contractile tissue) may include or be contractile cells.

[0073] The process further includes the production of a (solid) (porous) support that contains this contractile tissue and allows for the development of contractility. The expression "a (solid) (porous) support containing contractile tissue" means that all or part of a contractile tissue is located within the (solid) (porous) support, more specifically within the pores of the (solid) (porous) support. The cells within the (porous) support will adhere to the walls of the structure, and this stacking of cells, the interconnected whole, will allow for efficient synchronous contractile activity.

[0074] Stem cells, particularly mesenchymal stem cells, have inducible paracrine activity. The contractile tissue obtained in the compliant support comprises cells that have differentiated (generally, at least 80% of the stem cells, particularly mesenchymal stem cells, have differentiated).

[0075] Remarkably, the contractile tissue obtained in the (solid) support still exhibits paracrine activity which is inducible and even amplified with the appearance of specific factors when the cells are no longer in 2D but 3D culture, and when the cells have mostly differentiated into contractile cells.

[0076] This inducible or induced paracrine activity includes an immunomodulatory (paracrine) activity, notably immunosuppression, more specifically immunosuppression of T cells. The immunosuppressive activity of MSCs on T lymphocytes is not due to direct contact between MSCs and T lymphocytes. The immunosuppressive function of MSCs occurs through the activation of indoleamine 2,3-dioxygenase (IDO), which induces the consumption of tryptophan from the culture medium. This is largely responsible for the antiproliferative effect on T lymphocytes. This activation is also accompanied by the synthesis of numerous growth factors, which are released into the medium. Examples of released factors include epidermal growth factor (EGF). epidermal growth factor or EGF), platelet derived growth factor (PDGF), the blood platelet growth factor ( vascular endothelial growth factor or VEGF), the transforming growth factor ( transforming growth factor or TGFbeta), hepatocyte growth factor ( hepatocyte growth factor or HGF), insulin-like growth factor ( insulin growth factor such as IGF1), angiopoietin 1 (Ang1), keratinocyte growth factor ( keratinocyte growth factor or KGF), stroma-derived factor 1 ( stroma derived factor 1 or SDF1), follistatin-type protein 1 (Follistatin-like 1 / TSC36 or FSLT1), Interleukin 10 (IL-10), PGE2, metalloproteinases, and regulators such as MMP2, MMP9, T1MP1, and T1MP2. The majority of these cytokines have their secretions amplified in the 3D elastic compliance structure. Contractility support increases IL-1 and TGF-β signaling. IL-1 is the first mediator activated in inflammation after infarction and is responsible for the initial recruitment of inflammatory PMNs (polymorphonuclear neutrophils) in the first few hours. Numerous immunomodulatory factors are also released by activated MSCs, such as IDO, semaphorin-3A, B7-H4, LIF, TSG6, galectin, HO-1, IL-6, IL-10, TGF-β, PGE2, and PD-L1 / 2. Some released paracrine factors require a 3D structure with elastic compliance, such as TSG6 and CXCR4. TSG6 is known to play an important role in myocardial infarction. In 3D structures with elastic compliance, PGE2 production is particularly increased.Activation of cells in the support medium by interferon-gamma increases the synthesis of TGF-beta, PGE2, BMP2, factor H (a complement inhibitor), and Gal9. Factor H is crucial because the infarcted area contains a high concentration of complement, which can lead to local cell lysis. Factor H protects cells from complement-induced lysis, thus improving their survival. Thawed cells have decreased factor H levels and are therefore particularly susceptible to complement lysis. Their readiness for action is thus significantly enhanced. IL-10 is known to reduce the inflammatory response after myocardial infarction. IDO and PGE2 promote the transformation of M1 macrophages into M2 macrophages after myocardial infarction. As for the lysis of natural undenatured collagen, 2D cultured MSCs cannot lyse collagen because MMP14, MMP1, MMP8 or MMP13 activities are not present.MMP14 activity is that of a membrane-bound metalloproteinase that remains confined to the cell. Since MSCs remain within the surrounding tissue, this activity will also remain contained within the tissue. MMP14 activity can effectively lyse natural collagen, which is particularly overrepresented in the eschar area after myocardial infarction. MMP14 activity also modifies the activities of soluble metalloproteinases MMP2 and MMP9, which, once activated, will be capable of lysing natural collagen. These factors can then alter the surrounding natural collagen.

[0077] It has been shown that the paracrine factors released by the MSCs in vitro Immunosuppressive agents are factors that will promote tissue regeneration. in vivo. For example, paracrine factors released by immunosuppressive MSCs will accelerate the transformation of M1 macrophages into M2 type macrophages in infarction.

[0078] These factors may eventually be released in vesicles or in more complex membrane structures of the "exosome" type.

[0079] Inducible or induced paracrine activity can thus include (paracrine) activity of inhibiting the proliferation of T lymphocytes.

[0080] More specifically, inducible or induced paracrine activity is a (paracrine) activity that promotes immunomodulation (particularly immunosuppression) and that promotes cell generation and / or angiogenesis. More specifically, inducible or induced paracrine activity is a (paracrine) activity that promotes the immunosuppression of T cells.

[0081] The application process may therefore further include inducing paracrine activity in said contractile cells (or said contractile tissue, i.e., inducing paracrine activity in cells of this contractile tissue).

[0082] Inducing paracrine activity in said contractile cells (or cells of said contractile tissue) may include, in particular: the contact of these contractile cells (or this contractile tissue) with at least one paracrine activity-inducing agent chosen from IFNgamma (interferon gamma), TNFalpha (Tumor Necrosis Factor alpha) and IL1beta (interleukin 1 beta), more particularly with at least IFNgamma, more particularly with IFNgamma and optionally at least one other differentiation-inducing agent selected from TNFalpha and IL1beta, and / or the application of transient hypoxia to said contractile cells (or to cells of said contractile tissue), for example hypoxia of less than 5% for 1 or 2 days.

[0083] Contact with IFN-gamma can, for example, be carried out at a concentration greater than 10 IU / mL, more specifically at 50 to 1000 IU / mL, and more specifically at 50 to 500 IU / mL of IFN-gamma. As an alternative or in addition to the induction of paracrine activity in contractile tissue, the application process may include the induction of paracrine activity in stem cells, more specifically in mesenchymal stem cells, before they differentiate into cells forming contractile tissue. Thus, before inducing the differentiation of stem cells, more specifically mesenchymal stem cells, into contractile cells, more specifically into cells forming contractile tissue, the application process may include (as an alternative or in addition to the induction of paracrine activity in contractile tissue): the contacting of said stem cells, more particularly said mesenchymal cells, with at least one paracrine activity-inducing agent chosen from IFNgamma (interferon gamma), TNFalpha (Tumor Necrosis Factor alpha) and IL1beta (interleukin 1 beta), more particularly with at least IFNgamma, more particularly with IFNgamma and optionally at least one other differentiation-inducing agent selected from TNFalpha and IL1beta, and / or the application of transient hypoxia to said stem cells, more particularly to said mesenchymal cells (for example, hypoxia less than 5% for 1 or 2 days).

[0084] In addition to or as an alternative to being porous, the (solid) support used may exhibit an elasticity compliance of 0.1 to 30 kPa -1< , more particularly of 0.4 to 20 kPa -1< , more particularly of 0.5 to 15 kPa -1< , more particularly of 0.5 to 5 kPa -1< (compliance of the solid (porous) support with or without cell, more particularly without cell).

[0085] The elastic compliance of the substrate can be achieved after cell colonization and cross-linking. Cell colonization and cross-linking increase the elastic compliance of the substrate.

[0086] In the sense of materials science, the compliance of elasticity ( compliance Elasticity (in English) is a quantity that characterizes the elastic behavior of a material. Elastic compliance is defined as the inverse of an elastic modulus and is expressed in Pa⁻¹. Schematically, elastic compliance can be seen as the degree to which a container can withstand pressure or force without breaking.

[0087] The process as described in the application can thus be defined as a process for producing a contractile cellular biomaterial, which includes: the induction of the differentiation of multipotent mesenchymal stem cells into contractile cells in a contractility support which is a (solid) (three-dimensional) support, and the induction of paracrine activity of said contractile cells, the induced paracrine activity further including T cell immunosuppressive activity and / or indoleamine 2,3-dioxygenase (IDO) activation, said process further includes Inducing the differentiation of multipotent mesenchymal stem cells into contractile cells includes exposing the mesenchymal stem cells to at least one differentiation-promoting agent selected from TGFβ, CTGF, EGF, NUX1, transcription regulators, and mechanical stress and electrical stimulation, more particularly from TGFβ, CTGF, EGF, and NUX1, said three-dimensional (solid) support having an elastic compliance of 0.1 to 30 kPa, and inducing paracrine activity in said contractile cells includes exposing these contractile cells to at least one paracrine activity-inducing agent selected from IFNγ, TNFα, and IL1β, and / or applying transient hypoxia to cells of this contractile tissue. the (solid) contractility support containing the contractile cells thus produced being a contractile cellular biomaterial suitable for regenerative therapy of myocardial tissue.

[0088] More specifically, the application process can thus be defined as a process for producing a contractile cellular (bio)material suitable for regenerative therapy of myocardial tissue, which includes: the induction of the differentiation of mesenchymal stem cells into contractile cells and the production of a (solid) (porous) scaffold containing these contractile cells, and the induction of paracrine activity in these contractile cells, the induced paracrine activity including T-cell immunosuppressive activity, said process further includes Induction of mesenchymal stem cell differentiation into contractile cells includes contacting mesenchymal stem cells with at least one differentiation-promoting agent selected from TGFβ (more particularly with at least TGFβ1), CTGF, EGF and RUNX1, more particularly with at least TGFβ (more particularly with at least TGFβ1), more particularly with at least TGFβ (more particularly with at least TGFβ1) and optionally at least one other differentiation-promoting agent selected from CTGF, EGF, RUNX1, transcription regulators and mechanical stress, more particularly from CTGF, EGF and RUNX1; contractile cells include or are cells selected from myofibroblasts, fibroblasts, myocytes, cardiomyocytes, muscle cells (including mixtures of two, three, four or five of these cell types),more particularly include or are cells selected from myofibroblates and fibroblasts, more particularly include or are myofibroblates, said (solid) (porous) support exhibiting an elasticity compliance of 0.1 to 30 kPa, and the induction of paracrine activity in contractile cells includes bringing these contractile cells into contact with at least one paracrine activity-inducing agent selected from IFNgamma, TNFalpha, and IL1beta, more particularly with at least IFNgamma and optionally with at least one other paracrine activity-inducing agent selected from TNFalpha and IL1beta, and / or the application of transient hypoxia to these contractile cells.

[0089] More specifically, the process as described in the application can thus be defined as a process for producing a contractile cellular (bio)material suitable for regenerative therapy of myocardial tissue after infarction, and in that the contractile cells are chosen from myofibroblasts, fibroblasts, myocytes, cardiomyocytes and muscle cells and progenitors of these cells, and cells capable of differentiating into these cells.

[0090] More specifically, the process described in the application includes the following steps: induce the differentiation of mesenchymal stem cells into contractile cells which includes bringing the mesenchymal stem cells into contact with TGFbeta, more particularly with TGFbeta1, and induce a paracrine activity of said contractile cells which includes bringing the cells of this tissue into contact with IFNgamma.

[0091] The contractile cells described here form a contractile tissue within the (solid) (porous) support. The (solid) (porous) support containing the contractile tissue thus produced is a contractile cellular biomaterial suitable for regenerative tissue therapy, particularly for human tissues such as muscle tissue, non-contractile human tissue, and cardiac tissue, especially human myocardial tissue.

[0092] More specifically, the process as described in the application can be defined as a process for producing a contractile cellular (bio)material suitable for regenerative therapy of myocardial tissue, which includes inducing the differentiation of mesenchymal stem cells into contractile cells that, in the elastic compliance support, will form a contractile structure (in particular, contractile tissue), and inducing paracrine activity in these contractile cells, the induced paracrine activity including T-cell immunosuppressive activity. The process as described in the application includes the induction of the differentiation of mesenchymal stem cells into contractile cells and includes bringing the mesenchymal stem cells into contact with (at least) TGFβ, more specifically with (at least) TGFβ1 (and optionally at least one other differentiation-promoting agent selected from CTGF,EGF and RUNX1), , Contractile cells include or are cells selected from myofibroblasts, fibroblasts, myocytes, cardiomyocytes, muscle cells and their progenitors, a stem cell preparation containing mesenchymal cells, such as "cardiospheres" for example, for these cells (including mixtures of two, three, four or five of these cell types), more particularly include or are cells selected from myofibroblates and fibroblasts, more particularly include or are myofibroblates, said (solid) (porous) support has an elastic compliance of 0.1 to 30 kPa -1, and the induction of paracrine activity in contractile cells includes bringing these contractile cells into contact with (at least) IFNgamma (and optionally with at least one other paracrine activity-inducing agent selected from TNFalpha and IL1beta).

[0093] In one embodiment, stem cells (particularly mesenchymal stem cells) are placed or implanted in the (solid) (porous) support (particularly in the pores of this (solid) (porous) support) before their differentiation into cells forming contractile tissue is induced. All stem cells (particularly all mesenchymal stem cells), or at least 50%, 60%, or 80% of them, may be placed or implanted (or contained) within the porous (molecular) structure of the (solid) support.

[0094] The process as described in the application may then include placing or implanting (mesenchymal) stem cells in the (solid) (porous) support (more particularly in the pores of the (solid) (porous) support), and then inducing the differentiation of these (mesenchymal) stem cells into cells forming contractile tissue.

[0095] The induction of the differentiation of stem cells (mesenchymal) into cells forming contractile tissue and the production of a (solid) (porous) support that contains this contractile tissue can thus be achieved: by producing a (solid) (porous) support in which (in the pores of which) (mesenchymal) stem cells are contained and by inducing the differentiation of all or part (at least 50%, more particularly at least 80%) of these (mesenchymal) stem cells into cells which form contractile tissue (inside the porous structure of the (solid) support).

[0096] The cells that form contractile tissue can be linked together by intercellular junctions. These intercellular junctions can include connexin junctions (i.e., intercellular junctions whose junction proteins include one or more connexins). More specifically, intercellular junctions can include gap junctions, particularly connexon gap junctions.

[0097] Contractile tissue is, or is located, attached to the substrate. This contractile tissue is linked to the (solid) (porous) substrate, for example, by anchoring junctions. Anchoring junctions can be anchoring molecules. Anchoring molecules can include anchoring proteins, particularly at least one transmembrane protein linked to the cytoskeleton and the contractile apparatus of the cell. Anchoring junctions can also be anchoring molecules, including anchoring proteins, which include at least one integrin. These integrins are mechanoreceptors and thus determine the elasticity compliance of the substrate.Stimulation of receptors will induce an increase in cell connections between cells and also improve cell survival and promote differentiation into contractile cells and an organization of the contractile apparatus according to the location of this interaction, also strengthening it.

[0098] More specifically, the process as described in the application includes contractile cells that form a contractile tissue, and a contractile tissue that is linked to the contractility support by anchoring molecules that include at least one integrin.

[0099] The differentiation of stem cells, particularly mesenchymal stem cells, into cells forming contractile tissue can be induced until a cellular marker of differentiation is detected, said cellular marker being chosen, for example, from alphaSMA ( alphaSmoothMuscleActine and myosin (specifically type II myosin). The cellular marker in question is alphaSMA. Contractile tissue therefore contains cells that express at least the alphaSMA marker, specifically alphaSMA and myosin (specifically type II myosin). Within contractile cells in the contractility structures, alphaSMA will be associated with the contractility bands themselves, through integrin surface interaction.

[0100] The cells forming contractile tissue may be or include myofibroblasts, fibroblasts, myocytes, cardiomyocytes, and muscle cells (including skeletal muscle cells, smooth muscle cells, and striated muscle cells). Contractile tissue may also be a mixture of several of these cell types; for example, a mixture of at least two or at least three cell types selected from myofibroblasts, fibroblasts, myocytes, cardiomyocytes, and muscle cells, such as a mixture of myofibroblasts and fibroblasts.

[0101] The cells can be associated with other contractile or non-contractile cells, such as endothelial cells. Generally, all cells present in the heart can be associated.

[0102] More specifically, the cells forming a contractile tissue may be or include myofibroblasts that express the alphaSMA marker.

[0103] Contractile tissue is primarily composed of differentiated cells: generally, at least 80% of the cells that make it up are differentiated cells (which may, for example, express the myofibroblastic marker alphaSMA). However, the cells that form contractile tissue always express certain cellular markers that are usually observed on stem (mesenchymal) cells, and not on differentiated cells (which, in this case, may also express the alphaSMA marker and / or myosin).

[0104] For example, contractile tissue may include cells that are positive for one or more of the markers CD105, CD54, CD73, CD105 and CD90, more specifically for one or more of the markers CD105, CD54, CD73 and CD105.

[0105] For example, contractile tissue may include cells that are negative for one or more of the markers CD45, HLA-DR, CD14, CD19, CD34 and CD106, more specifically for one or more of the markers CD45 and HLA-DR.

[0106] Contractile tissue may include cells that are positive for one or more of the markers CD105, CD54, CD73 and CD105, and that are negative for one or more of the markers CD45 and HLA-DR.

[0107] Contractile tissue may, for example, include cells that are positive for the markers CD105, CD54, CD73, and CD105, and negative for the markers CD45 and HLA-DR. Thus, contractile tissue may include cells that are positive for the alphaSMA marker (and optionally positive for myosin), positive for the markers CD105, CD54, CD73, and CD105, and negative for the markers CD45 and HLA-DR.

[0108] Alternatively or complementarily, the differentiation of stem cells, particularly mesenchymal stem cells, into cells forming contractile tissue can be induced until the canonical Wnt signaling pathway is activated. Activation of the canonical Wnt signaling pathway can cause the accumulation of beta-catenin in the cytoplasm and its translocation to the nucleus to act as a transcriptional co-activator of transcription factors.

[0109] The contractile tissue retained inducible paracrine activity (specifically, inducible paracrine activity that promotes T-cell immunosuppression). The presence of inducible paracrine activity, particularly inducible paracrine immunosuppressive activity, is useful for the intended medical applications (control and reduction of the risk of immune rejection).

[0110] Induction of this paracrine activity can lead to: an activation or stimulation of the IDO (inducible indoleamine 2,3-dioxygenase) and / or an increase in the expression of certain proteins, including certain metalloproteinases such as MMP2, MMP9 and MMP14, and / or an increase in the expression of one or more of the molecules selected from TSG6 ( tumor necrosis factor Inducible gène 6), VEGF ( Vascular endothelial growth factor ) , PDGF ( Platelet-Derived Growth Factor ), angiopoietin, IL1 ( Interleukin-1 ), IGF1 ( Insulin-Like Growth Factor-1 ), FSL1 (synthetic lipoprotein Pam2CGDPKHPKSF), and PGE2 (Prostaglandin E2).

[0111] The induction of paracrine (cell) activity in said contractile tissue can therefore be achieved to the point of (in sufficient quantity and / or duration to) obtain one or more of the following: activation or stimulation of IDO, expression, or increased expression of at least one metalloproteinase (such as MMP9 and / or MMP2 and / or MMP14), more specifically up to (in a quantity and / or duration sufficient to) obtain one or more of the following: activation or stimulation of IDO, secretion, or increased secretion, of MMP9, secretion, or increased secretion, of MMP2, and expression (membrane), or increased expression (membrane), of MMP14, more particularly at least until activation or stimulation of IDO and / or expression or increased expression of one or more metalloproteinases, more particularly at least until activation or stimulation of IDO and / or secretion or increased secretion of MMP9 and / or MMP2, more particularly at least until secretion or increased secretion of MMP9.

[0112] Thus, after induction of paracrine activity, the contractile tissue can include cells that express MMP9, MMP2 and MMP14, more particularly those that secrete MMP9, MMP2, more particularly those that secrete MMP9.

[0113] Furthermore, it has been observed that inducible (or induced) paracrine activity can even be greater than that observed with undifferentiated stem cells. For example, the (differentiated) cells of the contractile tissue of the demand (contained in the porous substrate) can exhibit a secretion of metalloproteinase(s), particularly MMP9 and MMP2, and especially MMP9, that is greater than that observed with mesenchymal stem cells (in conventional 2D culture). This characteristic is favorable to angiogenesis and is therefore useful for the intended medical applications, particularly for regenerative therapy of myocardial tissue in the context of chronic myocardial infarction.

[0114] Thus, contractile tissue comprises contractile cells which include cells that express the alphaSMA marker and optionally myosin, and which, after induction by TGFbeta1, secrete at least one metalloproteinase chosen from MMP9 and MMP2 and MMP14.

[0115] The (porous) support with elastic compliance can be, for example, a gel, hydrogel, or shape-memory structure. The three-dimensional support can be in a liquid phase and, once delivered after activation, can be converted into a solid phase such as a solution, paste, gel, colloidal suspension, or plasma. The support can be a cryogel or an injectable support with shape memory. The constituents of the support can be intelligent agents capable of assembling, deforming, and potentially reassembling. These are materials that tend to assemble at the molecular level to form nano-, micro-, or macrostructures or combinations.

[0116] The support can be filaments, sponges, materials with a filamentary ultrastructure, a sponge-like honeycomb ultrastructure, structural analogs with interface shapes, powders, conduits, spheres, microspheres, films, micro- or nanofibrils, lipid membranes, fibers, matrices, patches, tissues, woven structures, or beta or alpha structures involved in their formation. The support can be composed of a combination of different supports or stacks of the same support. For example, it can be multilayer films obtained using microfluidics. The support can be fabricated using 3D printing techniques.

[0117] The (solid) (porous) support can be a woven or non-woven support, more specifically a gel, a hydrogel, a foam, a sponge.

[0118] The support can be made from monomers, polymers, or combinations. It can be made from natural or synthetic materials. Natural materials can potentially be produced using molecular biology techniques.

[0119] The substrate can be totally, partially, or not at all biodegradable.

[0120] The support can be made from polymers, monomers, natural or synthetic. All polymers can be used, whether synthetic, natural, or a combination thereof, provided the resulting support meets the differentiation and contractility properties defined previously, particularly in terms of elasticity. However, natural polymers with adhesion molecules are preferred. Among natural polymers is collagen. Collagen is the natural component of the extracellular matrix in tissues and is therefore particularly well-suited.

[0121] The support may contain or be made with a natural polymer such as collagen, gelatin, a collagen derivative, fibrinogen, fibrin, silk (including FIBROIN silk, which may be of particular interest due to its specific adhesion molecule), algae, alginate, proteoglycans, glycoproteins, glycoaminoglycans, agarose, hyaluronic acid, chitosan, fibrinogen / fibrin, carboxymethyl chitosan, sucrose octasulfate, dextran, cellulose, methylated cellulose, sepharose, a protein mimicked by SEPHADEX (such as latex), or a combination thereof. The properties of these polymers may be modified.The 3D support can come from the grouping of different supports: micro or nano tissue structures, filaments or tubes, sponge, powder, conduit, sphere, microsphere, film, micro or nanofibrils, membrane, fiber, mesh, matrix, patch, sheet of tissue, decellularized tissue (devoid of cells), knitted fabric, wadding or combination.

[0122] The three-dimensional scaffold contains collagen, which is composed of collagen types I, II, III, IV, V, VI, VII, XI, and others, or a combination of different types. The term "collagen" also refers to insoluble collagen, soluble collagen, and atelocollagen prepared by removing telopeptides from the ends of collagen molecules using a protease other than collagenase. It may be synthetic collagen or recombinant synthetic gelatin. The three-dimensional collagen scaffold can also be normal tissue of autologous, homologous, or heterologous origin. This tissue may be decellularized. Various protocols for tissue decellularization can be used (osmotic shock, ionic and nonionic detergents, proteolytic digestion, DNase / RNase treatments). Decellularization can be combined with techniques to modify the scaffold's properties, such as porosity.Decellularized tissue could potentially be used, but the problem with these tissues is their rigidity. Indeed, after cell extraction, the empty spaces compact, increasing rigidity. These tissues are also relatively non-porous. Methods to increase the porosity of these tissues make them more immunogenic and cause them to lose their mechanical properties.

[0123] Collagen can be purified from collagen-containing tissues: autologous, homologous, or heterologous, such as the ureter, pericardium, tissue matrix like the heart, submucosa like porcine intestinal submucosa (SIS), blood vessels, tendons, fascia, decellularized or non-cellular dermis, aponeuroses, amniotic membranes, and dura mater. It can also be produced as synthetic copies of collagen, such as polymer fibers or peptides forming fibrils. Collagen can be chemically modified, and the product obtained through succinylation, esterification, carboxyamide formation, or collagen deamination.

[0124] The scaffold can be made from synthetic organic polymers such as poly(lactic acid) (PGA) and / or poly(DL-lactide-Co-glycolide) (PLGA) and / or poly(DL-lactide-Co-caprolactone) (PCL), a collagen derivative such as gelatin, a polypeptide obtained by the hydrolysis of collagen, denatured collagen by heating. Synthetic polymers linked to collagen can be selected from Poly(3-hydroxybutyrate) (PHB)+++, poly(ε-caprolactone) (PCL), silk, polylactic acid (PLA), polyamide (PA), polylactic acid (PLA), polyglycolic acid (PGA), poly(L-lactic acid) (PLLA), PLGA, poly(anhydrides) (PA), polycarbonate (PC), hydroxy acids, polyorthoesters (POE), propylfumarates (PPF), polysaccharides, polylactone (PL), polycaprolactones, polyamides, polyamino acids, polyacetals, polyphosphazenes (PPZ), biodegradable polycyanoacrylates, biodegradable polyurethanes (central unit), polysaccharides, polypyrrole, polyanilines,Polythiophene, polystyrene, polyester (PE), non-biodegradable polyurethanes, polyureas, poly(ethylene terephthalate) (PET), poly(ethylene vinyl acetate), polypropylene, polymethacrylate, polyethylene, polycarbonates, polyethylene oxide, polyvinyl alcohol (PVA), Fuseau-Tex (polytetrafluoroethylene), Dacron (polyethylene terephthalate), polytetrafluoroethylene (PTFE), polyethylene glycol (PEG), polyglycerol sebacate (PGS), copolymers described above, with any of the above additives, and mixtures of any of the polymers, copolymers, and additives together, and combinations of synthetic derivatives with biological products.

[0125] Preferably, purified type I, II and III collagens will be used. Some collagens have specific adhesion properties and can therefore be combined as type IV collagen.

[0126] The scaffold can be a sponge-like matrix obtained by dehydration-hydrothermal crosslinking (DHT). It can also be a foam, such as a gelatin foam. This could be a collagen foam like GELFOAM™. DHT matrices are those obtained by dehydration-hydrothermal crosslinking. The manufacture of these supports may include a freeze-drying step where the temperature is lowered below zero degrees to increase the support's porosity, followed by high-temperature, low-pressure crosslinking to further crosslink the support. A matrix obtained by DHT corresponds to the ULTRAFOAM™ matrices from Bard. A matrix made with type I and type III collagen can be used as a hemostatic sponge. The initial collagen is soluble in a 0.5% w / w collagen solution in 0.05 M acetic acid at pH 3.5. The preparation is dried by controlled freezing to obtain sponges.The pore size and distribution depend primarily on the freezing rate (0.25-1°C / min) and the final freezing temperature (-90°C to -5°C). This sponge is then subjected to DHT crosslinking (105°C for 16 hours at a pressure below 100 mTorr) to introduce covalent bonds between the collagen chains without denaturing it into gelatin. During manufacturing, the substrate can be oriented by manipulating, for example, the temperature gradient.

[0127] Collagen can be combined with glycosaminoglycans. The scaffolds can potentially be manufactured using an electrospinning technique. (electrospinning) But the problem with this approach is that the substrates have a very high elasticity compliance and there is a difficulty in colonizing these substrates.

[0128] The substrate can be oriented. The substrates have a very high porosity, close to 98%. Porosity defines the substrate's capacity to allow liquids to pass through. The substrate may have a sponge-like structure at the ultrastructural level. This sponge-like structure promotes the initial entrapment of cells, with retention within the substrate. Some substrates also behave like sponges, drawing in liquids and fluids under the initial compression, and retaining both cells and liquids within the substrate. Initially, there is significant cell migration within the substrate, allowing for rapid colonization of the entire substrate within the first week. Once contractile structures develop, this migratory capacity is lost. This migratory capacity can potentially be used to colonize other 3D substrates placed in contact with it.This approach allows for very low-cost cell cultures in a 3D environment without the need for iterative cultures in 2D systems. Furthermore, this 3D culture enables the cultivation of more cells in a limited space.

[0129] The substrate may have intermediate-sized pores to allow nutrient diffusion and cell colonization. in vitro, cell colonization in vivo.

[0130] The porosity of the porous solid support is adapted to the presence of contractile cells within these pores. The porosity can range from 20 to 200 µm, for example, from 50 to 100 µm. This porosity can be homogeneous or non-homogeneous.

[0131] The support structure can be oriented. Oriented supports with greater elasticity favor differentiation towards contractile cells. The forces developed in oriented structures are greater. There is a synergistic effect between the orientation of the supports and any mechanical stimulation of these supports.

[0132] The support can be crosslinked. There are various methods of chemical crosslinking (such as aldehydes, isocyanates, carbodiimides), physical, biological, and combination crosslinking. Examples of physical crosslinking include UV and dehydrothermal (DHT). For chemical crosslinking, crosslinking agents that are preferably non-toxic to cells can be chosen, such as diphenylphosphorylazide, carbodiimides, EDC (1-ethyl-3-(3-dimethylaminopropyl-carbodiimide hydrochloride), EDC / NHS EDC (1-ethyl-3-(3-dimethylaminopropyl-carbodiimide hydrochloride) in the presence of NHS (N-hydroxysuccinimide), EGS (ethylene glycol-bis(succinic acid N-hydroxysuccinimide ester), and genipin). Glutaraldehyde can also be used if it is detoxified. Citric acid may be used as a crosslinking agent in electrospinning processes. electrospinning ") of collagen, for example. Enzymatic cross-linking, such as transglutaminasase, can also be used. Cross-linking can take place in vivo. The substrate can be cross-linked multiple times in vitro And in vivo. Chemical crosslinking reduces the number of cell adhesion sites. We propose combining crosslinking with adhesion molecules to improve scaffold functionality. We observed that it was possible to crosslink the scaffold with genipin (concentration <10 mM for 24 h at 37°C, optimal concentration 1.5 mM for 24 h at 37°C) without altering either the ability of cells to differentiate into contractile cells within the scaffold, or the preservation of the scaffold's contractility and the cells' inducible paracrine capacity. Crosslinking agents can influence cell differentiation capacity. This is very interesting because crosslinked scaffolds normally have greater rigidity and therefore lower contractility. We observed contractility in DHT scaffolds crosslinked with genipin or crosslinked with EDC / NHS.The cells differentiate into myofibroblasts, and inducible paracrine activity is the same in both reticular and non-reticular structures. Contractile activity remains present in reticular structures.

[0133] The structure of the porous solid support can take the form of a three-dimensional scaffold. It may, for example, include a polymer (such as those listed above) in a crosslinked form. The crosslinking of the polymer (e.g., collagen, particularly type I or type III collagen) can be achieved chemically, particularly with genipin (e.g., genipin at 0.1–10 mM) or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), and / or physically, particularly with hydrothermal dehydration crosslinking (DHT).

[0134] The elastic compliant support may also include adhesion molecules, particularly adhesion peptide(s), especially RGD (Arg-Gly-Asp) peptide molecules. Adhesion molecules include polynucleotides and adhesion peptides, which include peptides, polypeptides, proteins, or molecules capable of binding to cell adhesion receptors with high affinities, such as integrin receptors, according to current literature. Adhesion peptides may be composed of natural or synthetic amino acids and / or amino acids analogs. One or more amino acids in the adhesion peptide may be substituted. Adhesion peptides include peptides, polypeptides, proteins, or molecules (of natural or synthetic origin) containing the initial adhesion sequence. They may also be peptidomimetic structures capable of performing the same function as the peptide.The terms polypeptide, peptide, and protein can be used interchangeably. This also includes the addition of a chemical entity such as a carbohydrate group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a binding promoter for conjugation, functionalization, or any other organic or inorganic modification or association of a molecule, including polyethylene glycol (PEG) or any other synthetic molecule. These modifications may also include the cyclization of the peptide containing the adhesion sequence. Several adhesion peptides can be associated, and the peptide can refer to an individual peptide or a collection of peptides. The adhesion molecules or peptides can be modified and may also belong to the same molecule or to a molecule serving as an intermediary for binding to the substrate.

[0135] The peptide also includes adhesion peptides that interact with the adhesion receptor itself, as well as with co-receptors (not necessarily involved in adhesion). Binding to these co-receptors modifies and / or the adhesion and / or activation and / or transduction of the receptor.

[0136] Integrins that recognize natural collagen are alpha1, alpha2, alpha10 and alpha11 integrins associated with the beta1 chain.

[0137] As described in this application, the adhesion peptide could be the RGD peptide corresponding to arginine (R) - glycine (G) - aspartic acid (D), the integrin recognition motif on fibronectin described by Pierschbacher. et al. (“Linear RGD” Pierschbacher MD et al., Nature. 1984, May 3-9;309(5963):30-3), or on vitronectin as described by Plaff M. et al. ('cyclic RGD' Plaff M et al., J Biol Chem. 1994 Aug 12;269(32):20233-8). The 'RGD motif' also includes all peptide ligands that will interact with one of the integrin receptors, all the alphav receptors (5 receptors): αvβ1, αvβ3, αvβ5, αvβ6, αvβ8, αIIbβ3, α5β1, α8β1. Other adhesion peptides such as PHSRN peptides or extracellular matrix proteoglycan-binding domains (heparin-binding domains) based on XBBXBX (SEQ ID NO: 5) or XBBBXXBX (SEQ ID NO: 6), order patterns of BBXB (SEQ ID NO: 7), where B is a basic amino acid and X is a hydroxy amino acid, YIGSR (SEQ ID NO: 8) (Iwamoto et al., Science. 1987 Nov 20;238(4830):1132-4) and IKVAV (SEQ ID NO: 9) (-Ile-Lys-Val-Ala-Val-) (Tashiro et al., J Biol Chem. 1989 Sep 25;264(27):16174-82) RYWLPR (SEQ ID NO: 10) or RNIAEIIKDI (SEQ ID NO: 11) (Liesi P et al., FEBS Letters.Volume 244, Issue 1, 13 February 1989, Pages 141-148) of laminin, REDV (SEQ ID NO: 12) (Massia SP et al., J Biol Chem. 1992 Jul 15;267(20):14019), PHS (SEQ: ID NO: 13) (-Pro-His-Ser-Arg-Asn) (Aota S et al., J Biol Chem. 1994 Oct 7;269(40):24756-61) or KNEED (SEQ ID NO : 14) (Altroff H et al., J Biol Chem. 2001 Oct 1986;278; Wong. JY et al., Biomaterials 2002 Sep;23(18):3865-70) or EILDV (SEQ ID NO : 15) of fibronectin, the proteoglycan obligatory domain of adhesion proteins such as KRSR (SEQ ID NO : 16) (Dere KCome et al., 1998 Res. JC. 5;40(3):371-7 ; Rezania A et al., Biotechnol Prog. 1999 Jan-Feb;15(1):19-32) or FHRRIKA (SEQ ID NO: 17) (Rezania A et al., Biotechnol Prog. 1999 Jan-Feb;15(1):371-19): IDVA: PG. 18) and KQAGDV (SEQ ID NO: 19) of elastin (Mann & West et al., J Biomed Mater Res. 2002 Apr;60(1):86-93), GFOGER of type I collagen (Emsley J et al., Cell. 2000 Mar 31; 17(1):16-16), DERaben (41-5). KE et al., Oncogene. 2004 Jun 24;23(29):5056-67).

[0138] In one embodiment, the support is modified with a molecule corresponding to fibronectin, specifically the region containing the RGD motif. In fibronectin, RGD expression is linear, whereas in vitronectin it is the cyclic form.The sequences may for example be RGD, RGDS (SEQ ID NO : 20), GRGD (SEQ ID NO : 21), RGDV (SEQ ID NO : 22), RGDT (SEQ ID NO : 23), GRGDG (SEQ ID NO : 24), GRGDS (SEQ ID NO : 1), GRGDY (SEQ ID NO : 25), GRGDF (SEQ ID NO: 26), YRGDS (SEQ ID NO: 27), YRGDDG (SEQ ID NO: 28), GRGDSP (SEQ ID NO: 29), GRGDSG (SEQ ID NO: 30), GRGDSY (SEQ ID NO: 31), GRGDVY (SEQ ID NO: 32), GRGDSPK (SEQ ID NO: 33). (SEQ ID NO: 34), CGRGDSPK (SEQ ID NO: 35), CGRGDSY (SEQ ID NO: 36), cyclo(RGDfK) (SEQ ID NO: 37), YAVTGRGD (SEQ ID NO: 38), AcCGGNGEPRGDYRAY-NH2 (SEQ ID NO: 39), AcGCGYGRGDSPG (SEQ ID NO: 40) et RGDPASSKP (SEQ ID NO : 41), the cyclic variants of these peptides, the linear or branched multivalent variants (Dettin M et al., 2002, J. Biomed. Mater. res. 60:466-471; Monaghan S et al., 2001, Arkivoc, 2:U42-49; Thumshirn G et al al., 2003, Chemistry 9:2717-25; Scott ES et al., 2001, J.Gene Med.

[0139] For an adhesion peptide to be effective, if it is not included in the primary structure of the natural polymer, it must be attached to the substrate. If the adhesion motif is not covalently attached, it has the opposite effect on cells (no survival, decreased contractility). The adhesion motif serves as a bridge between the substrate and the cell's contractile apparatus and must therefore be attached. Adhesion peptide molecules, particularly RGD peptide molecules, can be linked to the (polymeric) structure of the solid (porous) substrate by a covalent bond, optionally via a spacer arm, more specifically a 30 to 40 Angstrom spacer arm.

[0140] The solid (porous) support can be completely, partially, or not biodegradable.

[0141] The solid support (and the biomaterial that contains it) does not include tumor extracts (of the MATRIGEL ® type), more specifically a protein extract from an Engelbreth-Holm-Swarm (EHS) tumor.

[0142] The process as described in the application includes a contractility support which is a three-dimensional scaffold of crosslinked polymer, more particularly of crosslinked collagen, which has a porosity of 20 to 200 µm, and which optionally includes adhesion peptide molecules, more particularly RGD peptide molecules, covalently linked to the polymeric structure of the solid support.

[0143] The support can be associated with an agent, in particular a coupling agent.

[0144] The agent may be associated in free form, absorbed, adsorbed, or bound. Binding may be reversible or association. The agent may be secreted by cells, or the product of these cells, including genetically modified cells, or produced by cells subjected to various stress conditions (hypoxic, chemical, physical, or other) or environmental stressors. The agent may be present in the carrier. in vitro, in vivo before, during, or after implantation of the support. The agent may optionally be bound to the support. Attachment may be reversible. The agent may be released from the support. Degradation of the support may allow control of agent release. The agent may be present in the form of a secretome or exososomes.

[0145] The agents can be, but are not limited to, proteins, oligoproteins, natural or synthetic peptides, DNA, microRNAs, mRNAs, and mitochondria. They can be growth factors, cytokines, chemokines, hormones, and drugs, for example. They can also be microvesicles or exosome-like structures. These exosomes can potentially be obtained from several cell types placed under conditions designed to obtain specific properties of these exosomes. Exosomes produced by one cell type can, for example, be used to… primer » another cell type that will be transplanted to it. For example, exosomes derived from cardiospheres can be used to activate priming a fibroblast that will be transplanted into him in vivo and not the cell that gives rise to exosomes.

[0146] Coupling agents can have a functional impact on the cells of the support or the support itself or a functional impact on myocardial cells or the cardiac extracellular matrix, cell recruitment and cell function particularly in the context of infarction (acute, subacute, chronic), ischemic heart disease, coronary ischemia, non-ischemic heart disease, myocarditis, heart failure, cardiogenic shock, myocardial conditions.

[0147] The support may, for example, be associated with agents promoting angiogenesis, antiarrhythmics, contractility, controlling ventricular remodeling, infarct size, effects on cell adhesion, survival, proliferation, regeneration, signaling ( signaling ), apoptosis, migration, the homing,Differentiation, cell-to-cell and cell-to-cell communication, contractility, cell recruitment, and the control of inflammatory and immune responses are all involved. The agent can be immunosuppressive or regenerative. Immunosuppressive agents can promote regeneration. in vivo. The agent can promote multi-stage cardiac repair, for example, by facilitating the use of subsequent, sequential, or repetitive cell therapy, or by employing multiple cell types. The agent can also preserve tissue for later cell therapy. The different agents and their effects can be combined.

[0148] This may involve agents that promote selectin-mediated cell adhesion, for example, by modifying the contractility support through modification with sugars.

[0149] The agent may optionally be delivered to the support or target therapeutic area of ​​the functionalized device via an additional device such as a ventricular restraint mesh, or a device designed to protect or maintain the restraint support. The factor may be delivered simultaneously or subsequently via endovascular routes: intracoronary injection, endovenous injection, systemic injection, intramyocardial injection (endoventricular, epicardial), injection into the pericardium, or release into the pericardium by devices not directly in contact with the heart but intended to treat it. The agent may also be produced from preparations located in non-cardiac ectopic regions and then transferred, or not, to the cardiac region, such as flaps ( flaps ) vascularized or avascular, or just a region of interest transferred to the free heart. The use of flapsepiploic for example or supports prepared in the peritoneal cavity and then applied to the heart or pericardial cavity.

[0150] Agents in general, including the cells described in the application, can be genetically modified using viral or non-viral modes of genetic modification.

[0151] These agents include factors involved in the differentiation of stem cells into contractile cells, the transformation of fibroblasts into myofibroblasts, factors involved in the induction of paracrine activity of MSCs, which can modify or prolong their secretion, or agents that allow control of cellular colonization of supports, including the inflammatory reaction.

[0152] Among the agents that can be associated with support are interferon Gamma, TGFbeta1, factors released by MSCs for example, factors that will increase the Wnt signaling pathway ( Wnt signaling ) especially the cathionic form Wnt / betacathenine of which Wnt3a.

[0153] The biomaterial can be subjected to a physical stimulus.

[0154] The substrate can be physically stimulated by being subjected to a mechanical stimulus such as electrical, mechanical (elongation, compression, extension), by being suspended from a spring or fixed (isometric stress), electromagnetic, or thermal. The substrate can also be electrostimulated. Electrostimulation plays a role in the differentiation of fibroblasts into contractile cells of the cardiomyocyte type. Electrostimulation also plays a role in the differentiation of fibroblasts into myofibroblasts. Mechanical stimulation decreases the differentiation of MSCs into adipocytes by inhibiting the SMAD pathways (" SMAD pathways ".

[0155] The process as described in this application presents a support for contractility which is a solid, a gel or a hydrogel, optionally crosslinked and / or optionally porous, which may have the structure of a sponge or a foam; and a support that can be associated with an agent and / or can be physically stimulated.

[0156] The substrate can be developed in a bioreactor.

[0157] The cellular support as described can be placed in a bioreactor. These bioreactors can, with a mechanical stimulus, which can be produced by fluid flow, for example, physically stimulate the cellular support. The application as described thus relates to a (novel) method for producing biomaterials in bioreactors combining different cell types and different stimuli. Electrical and mechanical stimuli can enhance the differentiation towards contractile cells and the paracrine activity of the associated cells.

[0158] The contractile biomaterial as described is specifically adapted for the regenerative therapy of myocardial tissue, particularly human myocardial tissue. It is especially suited for patients with ischemic and inflammatory myocardial tissue, for example, myocardial tissue that has suffered an acute or chronic myocardial infarction.

[0159] The contractile biomaterial as described can notably be intended to be administered via the pericardial route (during coronary bypass surgery, or during the placement of a mechanical cardiac assist device), via sternotomy, via mini-thoracotomy, via the xiphoid route, or via pericardiotomy and / or via a minimally invasive route.

[0160] The solid (porous) support (and therefore the contractile biomaterial) as described can be of any shape and size that a person skilled in the art deems appropriate, particularly with regard to the intended medical application (for example, with regard to the size of the targeted myocardial area), and with regard to the intended route of administration.

[0161] For example, it can be round, oval, ovoid in shape, and / or have a surface area of ​​0.5 to 10 cm², and / or a thickness of 0.1 mm to 1 cm.

[0162] The biomaterial as described in the application is contractile.

[0163] The contractile biomaterial as described in the application exhibits an elasticity compliance of 0.1 to 30 kPa -1<, more particularly of 0.1 to 3 kPa -1< for myofibrobasts and more particularly of 5 to 15 kPa -1< for other contractile cells.

[0164] The contraction and relaxation properties of the biomaterial are suitable for application on myocardial tissue. in vivo. These contraction and relaxation properties can be observed by applying a contraction stimulus that reduces one dimension of the biomaterial, and then by stopping the application of this stimulus. This contraction stimulus can, for example, be achieved through electrical stimulation in tetanus (e.g., applied with alternating current) or through chemical stimulation with KCl.

[0165] The relaxation of the cellular biomaterial can be of the same magnitude as the contraction that preceded it.

[0166] The cellular biomaterial responds to a Hill curve, meaning that it exhibits a contraction velocity that is hyperbolically related to the tension applied to it.

[0167] The contraction and relaxation kinetics of the cellular biomaterial are close to or substantially not different from those of the human placenta.

[0168] The cellular biomaterial in question may also exhibit elastic elongation properties: for example, it may be subjected to mechanical elongation of the order of 10% to 20%.

[0169] Remarkably, the contractile cellular biomaterial can be preserved without being frozen: simple hypothermia is sufficient.

[0170] Indeed, the cellular biomaterial retains contractility properties after being kept in isotonic solution for 5 days (especially for 5 to 10 days) at a temperature above 0°C and below 10°C (especially a temperature above 0°C and below 4°C).

[0171] The contractile cellular biomaterial as described can even retain inducible paracrine activity after being kept in isotonic solution for 5 days (in particular for 5 to 10 days) at a temperature above 0°C and below 10°C (in particular a temperature above 0°C and below 4°C).

[0172] The contractile cellular biomaterial described can therefore be stored simply in a refrigerator. The cellular biomaterial can, for example, be stored in an isotonic solution, serum or plasma, or in a cell culture medium. It can, for example, be contained in a cell culture plate, such as a 96-well plate, or in a cell culture tube (such as a 50 mL cylindrical tube).

[0173] Furthermore, the cellular biomaterial as described is immediately usable after preservation under hypothermic conditions.

[0174] The application as described relates more specifically to the contractile cellular biomaterial as described below and illustrated above and its medical applications.

[0175] A contractile cellular biomaterial obtainable by the process as described is suitable for regenerative therapy of myocardial tissue and comprises: an optionally porous solid support that exhibits an elastic compliance of 1 to 30 kPa -1< (compliance with or without cells, more particularly without cells), and a contractile cellular tissue that is contained within the optionally porous solid support, contractile cells including cells selected from myofibroblasts, fibroblasts, myocytes, cardiomyocytes and muscle cells and progenitors of these cells.

[0176] It may also exhibit IFNgamma-inducible paracrine activity, the inducible paracrine activity including T-cell immunosuppressive activity.

[0177] The biomaterial as described may also include an adhesive, such as a fibrin adhesive, at its periphery, intended to promote the biomaterial's adhesion to the myocardial tissue. This adhesive is, however, optional, as the material may exhibit spontaneous adhesion to the myocardial tissue.

[0178] The biomaterial as described can be stored at a temperature greater than or equal to 0°C, more particularly at a temperature greater than 0°C, more particularly at a temperature greater than 0°C and less than 32°C, more particularly at a temperature greater than 0°C and less than 10°C, in particular at a temperature greater than 0°C and less than 4°C.

[0179] The biomaterial as described can be stored beyond 24 hours, for example for 5 days or more than 5 days (in particular up to 10 days).

[0180] The biomaterial as described may be stored in any type of container that a person skilled in the art considers appropriate, for example in the well of a 96- or 24-well plate, or a cell culture tube (for example, a 50 mL cell culture tube).

[0181] The biomaterial as described can be stored in a medium such as a cell culture medium. The medium in which (or the solution in which) the biomaterial is stored or placed before administration does not have to be a hypothermic medium (or solution).

[0182] The biomaterial as described may allow for the control of cell migration in vitro And in vivo. The biomaterial as described can enable targeted cell therapy by preserving the cells within the scaffold in vivo and preserving their pro-regenerative immunosuppressive phenotype.

[0183] The biomaterial described in the application is intended for use in the treatment of acute (0-7 days), subacute (7 days to 1 month), or chronic (after 1 month) myocardial infarction to limit infarct size, preserve myocardial tissue, control ventricular remodeling, promote angiogenesis, and support cardiac regeneration. It can be used to treat myocardial insufficiency, particularly ischemic or post-infarction myocardial insufficiency (by healing infarcted myocardial tissue and / or restoring contractility of infarcted myocardial tissue). The biomaterial, with its secretion of numerous immunosuppressive and anti-inflammatory agents, may also be beneficial in the treatment of myocarditis. It may also be of interest in inflammatory cardiac diseases, such as rheumatic diseases.

[0184] The biomaterial as described in the application is intended in particular for use in the treatment of dilated or hypertrophic cardiomyopathy, myocarditis, pathological (or normal) aging of the heart, myocardial fibrosis, heart graft rejection, infectious heart disease (e.g. Chaga disease).

[0185] The biomaterial as described in the application can be used in the regenerative (or scarring) treatment of cardiac tissue, muscle tissue, or non-contractile human tissue, particularly in the treatment of post-infarction myocardial insufficiency. Specifically, it can restore contractility to myocardial tissue.

[0186] The biomaterial as described can also be implanted in contact with or within contractile muscle tissue, not necessarily cardiac, such as muscle tissue to deliver agents aimed at treating muscles or individuals in general.

[0187] The biomaterial as described can also deliver in vivo Targeted therapy is applied after contact with pathological tissue to promote its regeneration. The support helps to protect cells from the inflammatory reaction and to preserve the pro-regenerative immunosuppressive phenotype. in vivo. The engagement of cells in contractile structures will prevent their migration in vivo. This will allow cells to remain in the delivery site, thus enabling the delivery of targeted therapy. Possible applications include, for example, the liver.

[0188] Our approach to the storage, transfer, and delivery of multipotent MSCs does not require freezing the cells, at least not during the final stage. Instead, the approach involves differentiating the multipotent MSCs within a 3D scaffold using appropriate factors. This scaffold allows the cells to interact with each other and with the scaffold itself, enabling them to organize into tissue structures such as bone, cartilage, or adipose tissue. Within these structures, the MSCs can be transferred at a hypothermic temperature (below 0°C), preferably between 0 and 10°C. EXAMPLES Example 1 : production of a contractile biomaterial Preparation of the porous solid substrate

[0189] Four types of matrices were produced: a hydrothermal dehydration (DHT) crosslinked collagen matrix, a DHT crosslinked collagen matrix comprising adhesion peptide molecules, namely RGD (Arg-Gly-Asp) molecules, a genipin crosslinked collagen matrix, a genipin crosslinked collagen matrix comprising RGD peptide molecules.

[0190] A DHT-crosslinked collagen matrix was produced. The DHT-cured matrix corresponds to Bard's Ultrafoam™ matrices. The matrix was manufactured using type I and type III collagen and used as a hemostatic sponge. The initial collagen is soluble in a 0.5% w / w collagen solution in 0.05 M acetic acid, pH 3.5. The preparation is cryogenically dried to obtain sponges. The pore size and distribution depend primarily on the freezing rate (0.25–1°C / min) and the final freezing temperature (-90°C to -5°C). This sponge is then subjected to DHT crosslinking (105°C for 16 h at a pressure below 100 mTorr) to introduce covalent bonds between the collagen chains without denaturing it into gelatin. Collagen fibers spontaneously tend to group together in a porous structure.This capacity remains with gelatin, but the porosity is lower. During freezing, it is possible to create a thermal gradient to orient the support.

[0191] The matrix can also be produced in the form of a porous gelatin foam (“ foam templating ").

[0192] A gaseous phase (nitrogen) is generated by the reaction between sulfamic acid and sodium nitrite in a gelatin solution, in the presence of a surfactant polymer and SDS. The foam is prepared at 45°C and then cooled to 5°C to allow it to set. After purification, the physical gel is self-crosslinked with EDC and can be lyophilized. The voids and interconnections are on the order of 230 and 90 microns, respectively.

[0193] Genipin-crosslinked collagen matrix was produced. We observed that it was possible to crosslink the scaffold with genipin (concentration <10 mM for 24 h at 37°C, optimal concentration 1.5 mM for 24 h at 37°C). Genipin can be used at concentrations between 0.1 and 10 mM. At higher concentrations, genipin is toxic to cells. Crosslinking can be performed at room temperature or at 37°C. Crosslinking of the scaffold is accompanied by varying degrees of crosslinking of the scaffold itself. Crosslinking can last up to 3 days, but tissues can remain crosslinked for up to 1 month. The higher the temperature, the faster the crosslinking.

[0194] For the covalent fixation of the RGD motif we used a linker (“ crosslinkerThe heterobifunctional sulfo-LC-SPDP allows coupling of an NH2 site on the peptide with an amine site present on collagen. By modifying both the collagen and the peptide, we were able to unidirectionally bind the molecule with the introduction of a 36 Å spacer arm. Binding lasted 48 hours. During binding, thiol groups were released into the medium, allowing us to determine both the number of available NH2 sites on the collagen and the number of RGD molecules bound to the support.

[0195] The optimal spacer is around 36 Angstroms (40-50 Angstroms), with a gradual effect from zero Angstroms to 35. Preferably, the linker can be flexible and hydrophilic. In one embodiment, the linker can be made of amino acids only, without the participation of the agent used for cross-linking. crosslinkingin the spacer. Glycine-type amino acids can be used. The spacer for each glycine is approximately 3.4 Å. This allows for oligopeptides containing the GRGDS motif (SEQ ID NO: 1) and the spacer -GSGGGGGGS-GRGDS (SEQ ID NO: 2) or -GGGGGGGGG-GRGDS (SEQ ID NO: 3). The presence of an S amino acid improves peptide presentation at the membrane. The oligopeptide containing the RGD will then be attached to the -NH2 of collagen via a conventional azide or isocyanate-type chemical reaction. Alternatively, molecules of the type ---CGSGGGGGGGS-GRGDS or CGSGGGGGGGS-GRGDS can be used, along with succinimidyl iodoacetate C6H6INO4 (SIA) (a zero-linker for peptide-collagen coupling). The idea is to have a 36 Angstrom spacer made primarily of wisteria.A spacer arm can be formed, part of which is a synthetic polymer such as HOOC-H2CH2C-PEH8-NH2. SIA can be used to attach the C-GRGDS oligopeptide via an -SH group, and EDC / NHS, EDC, or Sulfo-NHC can be used to link the carboxylic acid group to the -NH2 group of the collagen. By using Sulfo-LC-SPDP, the cost can be reduced by using a modified peptide containing an -SH group, such as a cysteine ​​of the type -C-GGGG-GRGDS (SQ ID NO: 4). This provides a cysteine ​​with a thiol group to which the collagen can be attached using Sulfo-LC-SPDP. The final attachment will result in a spacer arm of 36 angstroms.

[0196] For matrices containing G-RGDS peptide, the "RGD" peptide was used at a ratio of 1 mg per 10 mg of collagen. The RGD peptide molecules were covalently attached to the collagen molecules of the support by solid heterogeneous phase functionalization, using sulfosuccinimidyl 6-(3'-(2-pyridyldithio)propionamido)hexanoate (sulfo-LC-SPDP).

[0197] Genipin cross-linking did not alter the binding of adhesion molecules. However, in vivo, Matrix resorption control in immunocompetent rats is superior if matrices are cross-linked prior to modification with adhesion molecules.

[0198] In each matrix produced, the pore size was between 20 and 200 µm.

[0199] Each matrix produced was cut into discs 6 mm in diameter and 3 mm thick. When immersed in the culture medium, the thickness of the matrices decreases by 20%. The cutting of the matrices is not critical because the cells have the ability to migrate within the matrix. If the cell concentrations are very high, a short centrifugation can be used to improve the initial seeding. The thickness of the human myocardium is 10 mm.

[0200] Each disc can individually serve as a solid porous support.

[0201] Isolation of mesenchymal stem cells.

[0202] Mesenchymal stem cells ( Mesenchymal Stem Cellsor MSC) were isolated from hematopoietic marrow present in human femoral heads. These femoral heads were derived from tissues that had been sacrificed during prosthetic hip replacement. Cell isolation was performed on the mononuclear fraction of cells from this marrow. The iliac crest was aspirated from the resected femoral head. Each aspirate (3–30 mL) was collected in an EDTA tube. The aspirates were diluted 1:1 in HBSS solution. (Hank's Balanced Slat Solution).Mononuclear cells were collected by centrifugation with a 1000 G density gradient for 20 min through tubes containing UNI-SEP Maxi (polysucrose-sodium metrizoate). The mononuclear fraction was collected and washed with HBSS. The cells were stained with trypan blue to identify and collect live cells. The collected cells were cultured on expansion medium in standard cell culture flasks (NUNC® < 75 cm² < ) at a density of 250,000–300,000 cells per flask. The cultures were incubated at 37°C under 5% CO₂.

[0203] The expansion medium was a DMEM medium (Dulbecco's Modified Eagle Medium low glucose, SIGMA-ALDRICH ®< ) supplemented with 0.05 mg / mL gentamicin, 2 IU / mL heparin, 0.001% 2-Mercaptoethanol (SIGMA-ALDRICH ®< ), 1% non-essential amino acid, and 10% platelet lysate.

[0204] The platelet lysate was prepared from PRP plasma (Plasma-Rich Platelet) The plasma was obtained from the French Blood Establishment (Etablissement Français du Sang) and tested negative for HIV, HTLV, HCV, and HBV. Bags containing the PRP plasma were stored at -80°C and warmed to 37°C in a water bath. After warming, the PRP plasma from multiple donors was mixed and centrifuged at 14,000 G for 10 minutes to remove platelet particles and membranes. The platelet lysate supernatant was collected and frozen at -80°C until use. The platelet lysate was tested for the absence of bacterial endotoxins, hemoglobin (purity), pH, total protein, albumin, osmolarity, sterility, and the absence of mycoplasma.

[0205] Cells that adhere to the plastic of the culture dish (after 24 hours of contact with the plastic surface) and that exhibit the full range of MSC markers (cells positive for CD105, CD73, and CD90, and negative for CD45, CD34, CD14, CD19, and HLA-DR) were selected. These cells are capable of differentiating into adipocytes, chondroblasts, and osteocytes.

[0206] The isolated MSCs can be cultured on expansion medium until use (the medium being renewed when the cells reach confluence, the cells being detached with trypsin for 5 min at 37°C).

[0207] During the preparation process, MSCs may be frozen. MSCs can be frozen up to at least the 10th passthrough. After thawing, the MSCs can be amplified again in standard amplification media before being attached to the support. The resulting biomaterials will then no longer be frozen for storage, delivery, and transfer. This process induces the differentiation of mesenchymal stem cells into cells forming contractile tissue within the porous solid support.

[0208] Porous solid supports were placed in culture well plates, one support per well. Isolated MSCs were added at a rate of 10⁵ cells per support to a volume of 10 µL of expansion medium (containing platelet lysate, and therefore TGFβ1). They can be deposited on the surface of the porous solid support. The plates were incubated at 37°C for 9 to 30 days. The expansion medium was changed every two days. The contractile and immunosuppressive properties of the cells were preserved during this period. After one month, the metalloproteinase enzymes secreted by the MSCs gradually led to the destruction of the support and reduced contractility if the preparations were maintained at 37°C. The MSCs migrated within the volume of the porous solid support and colonized it homogeneously.After four days, the MSCs have massively differentiated (over 80%) into cells forming contractile tissue within the pores of the porous solid support, starting on day 8. If desired, incubation can be continued for at least 45 days.

[0209] The collagen scaffold we used can be digested with type II collagenases (for 15 min–1 h at 37°C). The cells can then be recovered, and it is possible to analyze their number and survival. We have developed a specific cytometry for alpha-SMA cells to quantify these cells in the preparation. It is also possible to perform co-labeling for alpha-SMA cells and other mesenchymal markers. However, in our preparations, in accordance with our semi-quantitative histological analysis, the majority of cells are alpha-SMA cells and express mesenchymal cell markers. In the scaffolds, cell viability is around 95% under normal stress conditions. We did not observe a difference in survival in the presence or absence of RGD. There is only minimal cell proliferation, just 20–30% over two weeks. However, we observe massive cell differentiation.Between matrices with or without RGD, the level of differentiation is the same, however the association of alphaSMA to the contractile apparatus may be different and could explain the difference in contractility of the different preparations.

[0210] We also analyzed these cells using conventional microscopy. We observed no difference between the outside and inside of the support. Interestingly, initially, the cells are able to colonize any type of support. They can be placed at the end of a cylindrical support, and they will colonize the support, probably due to the size of its pores. Colonization occurs primarily from the inside out. If we apply supports to young cell preparations, the cells will migrate from one support to another by forming bridges. Subsequently, a fairly substantial layer forms on the surface. However, if supports are placed in contact with these cells, they no longer migrate. We confirmed the colocalization for the alphaSMA and myosin markers using confocal microscopy.

[0211] Contractile tissue comprises cells that express the myofibroblastic marker alphaSMA. These are therefore contractile cells.

[0212] In electron microscopy, even in the absence of RGD peptide molecules, cells could be observed with a stress band organization and a sarcomeric-type organization, with alternating bands approximately every micrometer: cf. Figure 1 .

[0213] Under the electron microscope, the cells differentiated from the MSCs exhibited the characteristics of myofibroblasts with the presence of a basement membrane, a highly developed endoplasmic reticulum, a particulate organization of the cells with a fibronexus-type extracellular matrix, and adherens junction-type intercellular junctions. Figure 1The drawn rectangles delineate identifiable areas of contractile filament proteins. The arrows indicate regular interruptions of these filaments by dense bodies or possibly sarcomeres. Regardless of the apparatus's organization, we observe here, only in the contractility support of the demand, a terminal organization of the contractile apparatus.

[0214] Interestingly, the mesenchymal cells also expressed stress bands with alternating 1-micrometer bands, suggesting a sarcomeric-type organization. These structures are abundant and not only at the membrane adhesion zone. We observed these structures in collagen scaffolds with and without adhesion molecules such as RGD, and also in chemically cross-linked scaffolds.

[0215] This highlights in vitrothe formal link between mesenchymal stem cells and myofibroblastic-type contractile cells. We show that MSCs in vitro They can differentiate into cells other than chondrocytes, osteocytes, and adipocytes, namely into fully differentiated myofibroblasts. The interactions between cells and the extracellular matrix, and between cells themselves, are extremely well developed.

[0216] These organized structures of the contractile apparatus in vitroTo our knowledge, these features have not been demonstrated in contractile cells derived from MSCs in 2D cultures. More specifically, these stress bands and the terminal organization of the contractile apparatus have, to our knowledge, never been demonstrated with MSC-derived cultures. The biomaterial in question therefore allows for the terminal differentiation of contractile cells. Tests performed in the absence of platelet lysate show a lack of differentiation of MSCs into contractile tissue. The addition of TGFβ1 restores the differentiation of MSCs into contractile tissue in the porous solid support.

[0217] It is also possible to use MSCs present in cell cluster preparations as "cardiosphere" preparations. Cardiospheres are the cells currently developing for regeneration after myocardial infarction. Allogeneic or autologous cardiospheres can be used. Human cell clusters (cf. "cardiosphere") are obtained from human myocardial biopsies and are enriched with MSC-type stem cells and C-kit+ cells.

[0218] The cardiospheres have been put in vitro in DHT RGD collagen matrices or EDC / NHS crosslinked gelatin foams for 7 days. In the 3D RGD collagen scaffold, cells migrate out of the cluster and colonize the entire scaffold. There is a significant increase in cardiac markers. (cf. Figure 5There is also a decrease in the stress proteins Hsp70, Hsp72, and Hsp90. In other cell preparations, we also observed activation of the Akt survival pathway in support-associated cells. Akt activation could partly explain the improved cell survival under hypothermic stress conditions. Example 2 : contractility of the biomaterial

[0219] The contractility of the biomaterials in Example 1 above was tested by electrical stimulation (tetanic contraction induced by alternating current) and by chemical stimulation with KCl (0.05 M), following the same protocol as that applied to placental tissue as described in Lecarpentier et al. 2013 (Placenta 34: 1163-1169) and Lecarpentier et al. 2015 (PLoS ONE 10(11): e0142471).

[0220] The biomaterials in Example 1 were stored in a refrigerator at a temperature above 0°C and below or equal to 4°C until use. They were then placed in a bath at 30°C for 30 minutes and subjected to contractility tests.

[0221] For mechanical stimulation, tests can be performed after simple warming to room temperature. The preparations are extremely stable throughout all measurements, which are carried out over several hours, with the same responses at the beginning and end of the experiment. The preparations can be returned to the refrigerator, and the same type of response can be observed on subsequent days.

[0222] Following electrical stimulation in tetanus, there is a significant shortening of the connective tissues. This shortening ceases when the stimulation stops. (cf. Figure 2Interestingly, the kinetics of contraction and relaxation are very similar, with a return to the basal state following the same kinetics. Like contraction, relaxation is a phenomenon driven by the cellular component associated with the support. Relaxation is a dynamic, not passive, mechanism (if relaxation were passive, there would be difficulty in cardiac filling, which could lead to diastolic heart failure due to impaired ventricular filling). Remarkably, the kinetics of contraction and relaxation are close to those of placental tissue.

[0223] The tests were then replicated by maintaining the contraction stimulus (electrical current or KCl) and adding to the medium either an inhibitor of the actin-myosin interaction (namely 2,3-butanedione monoxime (BDM) at 4 mM) or an activator of the nitric oxide and cyclic guanosine monophosphate (NO-cGMP) pathway (namely isosorbide dinitrate (ISD or RISORDAN™) at 1.7 × 10⁻⁴ M). The induction of NO in the preparations indicates that they are viable and highly functional, as at least four intracellular cascades are involved in achieving relaxation.

[0224] The results are illustrated by the Figure 3A (case of a biomaterial with a DHT-crosslinked collagen matrix and RGD peptide molecules, under electrical stimulation in tetanus and with inhibition by RISORDAN™) and by the Figure 3B(Case of a biomaterial with a DHT-crosslinked collagen matrix, stimulated by 0.05 M KCl, and inhibited by BDM). It was observed that the inhibitor (RISORDAN™ or BDM) induces relaxation even if the stimulus that caused contraction (electrical current or KCl) is maintained. This demonstrates that relaxation is an active phenomenon mediated by the contractile units (actin and myosin) of the biomaterial tissue.

[0225] It has been observed that the presence of adhesion molecules (RDG peptide) increases contractility parameters, generally by a factor of 2 or 3.

[0226] In a completely exceptional manner, a Hill curve was able to be established. (cf. Figure 4 ), which is characteristic of muscle contractile tissues after KCI or electrical stimulation. The curves we observed are very similar to those that have been described for explanted human placental tissue.

[0227] The elastic compliance of the substrates was determined. For the collagen substrate, the elastic compliance without cells was 0.4 kPa⁻¹. The elastic compliance of the cell-colonized substrates was 1.5 kPa⁻¹. Example 3: Induction of paracrine activity

[0228] T lymphocytes were labeled with the cytoplasmic intracellular fluorescence marker CFSE (whose fluorescence is divided by two at each cell division), and were activated by antiCD3 and antiCD28 for 48h.

[0229] The biomaterials in Example 1 were incubated with IFNgamma at 500 IU / mL for 7 days.

[0230] Before and after this incubation with IFNgamma, the supernatants of the biomaterials were placed in contact with activated and labeled T lymphocytes.

[0231] Tryptophan consumption was measured in the incubation medium (using the Boxam-Warren method). Tryptophan consumption in the medium of MSCs is due to IDO activation. In the incubation medium of biomaterials not stimulated by IFN-gamma, there was virtually no tryptophan consumption. In contrast, in the incubation medium of biomaterials stimulated by IFN-gamma, high tryptophan consumption was observed. This is of the same order of magnitude as that which would be observed with a standard 2D culture of undifferentiated MSCs. However, there is very little cell proliferation in the biomaterial compared to a (standard 2D) culture of undifferentiated MSCs. The paracrine function of the biomaterial is therefore greater than that of a (standard 2D) culture of undifferentiated MSCs.

[0232] CFSE fluorescence was measured. It can be observed that the biomaterial (with MSCs differentiated into myofibroblasts at more than 80%) inhibits the proliferation of B lymphocytes whether it is based on cross-linked collagen or on DHT-cross-linked collagen with RGD peptide molecules.

[0233] The expression of various factors related to paracrine function, including the expression of cytokines and metalloproteinases, was measured.

[0234] In particular, an increase in the expression of metalloproteinases MMP9, MMP2 and MMP14 was observed (especially on day 7), after stimulation of the biomaterial by IFNgamma, and in particular an increase in the secretion of MMP9 and MMP2, more particularly of MMP9.

[0235] It was therefore observed that, although in the biomaterial the MSCs differentiated into cells forming a contractile tissue, the inducible paracrine activity was not lost. It even appears to be increased. Example 4 : storage without freezing

[0236] The biomaterials in Example 1 were stored for 10 days in a refrigerator (at a temperature of approximately 4°C). The contractility and paracrine function of these biomaterials were measured as described in Examples 2 and 3 above. No alteration in contractility or paracrine function was detected. The biomaterials can therefore be stored without freezing and are immediately functional.

[0237] In contrast, undifferentiated MSCs preserved by freezing only regain paracrine function after 7 days following thawing.

[0238] The biomaterials could also be sent by mail in the usual way, in polystyrene containers. The biomaterials were in their culture medium, containing serum and antibiotics, in 50 mL tubes. Inside the polystyrene, to maintain a low temperature around zero degrees Celsius, ice packs (like those used in coolers) and, if necessary, dry ice were added, while avoiding direct contact with the tube containing the biomaterial. Upon arrival, the tubes containing the biomaterials were stored in a refrigerator between 0 and 4°C. In some cases, preparations arrived after 6 days without any particular problems, even if the dry ice was no longer present.

[0239] Ice packs, similar to those used for delivering pharmaceutical products (such as CRYOPACs), can be used to prevent freezing and maintain specific temperatures, preferably between +2°C and +8°C. The temperature inside the container can be monitored. If the preparation medium needs to be changed, the biomaterials containing the cells can be transferred to a new container with the appropriate medium. This transfer can be performed in the operating room or under a suitable laminar flow hood.

[0240] Another solution, to avoid exposing the preparation to the open air, is to make this modification in a confined environment.

[0241] One solution is to use several tanks in series. The first tank contains the desired final medium, the second holds the cells with their support structure, and the third tank can be empty and used as a waste container. The number of tanks and their arrangement can be varied. They do not necessarily all have the same volume. There can be communication channels between the tanks, with the option of using closure or non-return valve systems. Bacterial filtration systems can also be incorporated. Example 5: Post-myocardial infarction therapy in an animal model

[0242] The biomaterials in Example 1 were administered to rats used as models of myocardial infarction.

[0243] A rat model of myocardial infarction was developed as described in Vallée et al. 2012 (Stem Cells Translational Medicine 1:248-260). 250 g OFA (Oncins France strain A) rats were obtained from CHARLES RIVER (Wilmington, MA, USA). The rats were immunosuppressed with tacrolimus (8 mg / kg / day in two injections) before surgery and for 45 days. The rats were anesthetized with a mixture of ketamine 100 mg / kg and xylazine 10 mg / kg administered by intraperitoneal injection and were ventilated after tracheal intubation. A left thoracotomy was performed to access the heart and pericardial cavity. The myocardial infarction was produced by a definitive ligation of the anterior intraventricular artery with PROLENE™ suture thread < 6 / 0.The infarction is accompanied by an ST segment elevation on the electrocardiogram, localized cyanosis in the area downstream of the occluded vessel and akinesis of the area (in this case of the anterior myocardium).

[0244] The size of the infarct and left ventricular function were measured by MRI on days 2, 7, and 45. Ligation of the anterior intraventricular artery caused a 25% reduction in infarct size, which remained stable over time. The left ventricular ejection fraction (which is 68% normally without ligation and infarction) decreased to 53% on day 2, then to 45% on days 7 and 45.

[0245] The biomaterials in Example 1 were stored for 7 days in a refrigerator (temperature of 4°C), then placed in contact with IFN-gamma for 5 days at room temperature. The biomaterials were placed on the infarcted area (with optional PROLENE™ suture).

[0246] The size of the infarct is only 10% at day 7 (biomaterial of example 1 with DHT crosslinked collagen matrix and MSCs differentiated into myofibroblates), whereas it remains at 25% with an injection of undifferentiated MSCs.

[0247] The left ventricular ejection fraction is 60% on day 2, 59% on day 7 and 58% on day 45 of the biomaterial in example 1 with DHT-crosslinked collagen matrix and MSCs differentiated into myofibroblates, whereas it is 54%, 52% and 49% on days 2, 7 and 45, respectively, with a biomaterial in which MSC differentiation has not been induced (non-contractile biomaterial).

[0248] The biomaterial in Example 1 (DHT-crosslinked collagen matrix; MSCs differentiated into myofibroblates) reduces ventricular dilation after myocardial infarction, particularly diastolic ventricular distension. It also increases systolic segmental contractility, which the non-contractile biomaterial (non-induced MSC differentiation) cannot achieve.

[0249] Human MSCs transfected with RLuc have been identified in vivo After injection of the substrate for luciferase on days 1, 4, 8, and 25, with collagen patches containing non-contractile multipotent cells, there is a massive decrease of approximately 75% on day 4, whereas this decrease is delayed with contractile patches, whether or not they contain RGD. At one month, with collagen-based contractile patches, 30% of the cells are still present, and 50% if the contractile patches contain collagen-RGD. Example 6: possibility of using this approach outside the core

[0250] In vivo Collagen scaffolding enhances the initial retention of undifferentiated multipotent stem cells (MSCs) in contact with muscle tissue. However, MSCs exhibit secondary migration within collagen matrices. Differentiation of MSCs into contractile cells delays this migration to more than two weeks. It has been shown that MSCs do not necessarily need to be permanently present, but their initial level of engraftment largely determines their effect.

[0251] We have developed a cell tracing system in vivoAfter transfection of these cells with the luciferase gene, multipotent human MSCs were labeled. The multipotent MSCs were cultured for 48 hours in the culture medium. After 4 days, only 50% of the cells had disappeared locally, and less than 10% of the cells remained from day 8 until 1 month. These results are, however, superior to those obtained when MSCs are injected free-floating into the thigh, where less than 10% of the cells are present after 24 hours.

[0252] Therefore, the presence of cells in a substrate improves their retention on day 1. We compared substrates with cells differentiated on day 9 into contractile structures. With these patches, on day 4, almost 100% of the cells were still present. From day 8 onward, there was a decrease in the number of cells, and 50% of the cells were present by day 11. At one month, 20% of the cells remained. Collagen patches showed a slight superiority over RGD. The differentiation of MSCs into contractile structures reduces the secondary migration of these cells. in vivo.

Claims

1. A method for producing a contractile cellular biomaterial, characterized in that the process comprises: - placing mesenchymal stem cells inside a three-dimensional support, said support having pores allowing the diffusion of nutrients, and cell colonization in vitro, and in vivo, - inducing the differentiation of multipotent mesenchymal stem cells into contractile cells, chosen from myofibroblasts, myocytes, cardiomyocytes, or striated muscle cells, in a three-dimensional support with elasticity complacency that allows the formation of contractile tissue by bringing said mesenchymal stem cells into contact with a differentiation-promoting agent chosen from TGFbeta, CTGF, EGF, NUX1 and platelet lysate, and - inducing paracrine activity of said contractile cells, the induced paracrine activity also including T cell immunosuppression activity and / or indoleamine 2,3-dioxygenase (IDO) activation, said paracrine activity is induced by the contact of these contractile cells with at least one paracrine activity inducing agent chosen from IFNgamma, TNFalpha and IL1beta, and / or the application of transient hypoxia on these contractile cells, in which said three-dimensional support has a compliance without a cell from 0.1 to 30kPa-1, especially from 0.4 to 20 kPa-1, especially from 0.5 to 15 kPa-1, especially from 0.5 to 5 kPa-1, said carrier containing the contractile cells thus produced being a contractile cell biomaterial suitable for the regenerative therapy of myocardial tissue.

2. The method according to claim 1, characterized in that said support is chosen from a natural polymer selected from collagen, gelatin, fibrinogen, fibrin, FIBROIN silk, alginate, a proteoglycan, a glycoprotein, a glycoaminoglycan, an alginate, agarose, hyaluronic acid, agar, chitosan, fibrinogen / fibrin, carboxymethylated chitosan, sucrose octasulfate, dextran, cellulose, methylated cellulose, sepharose, or a combination thereof, or an organic synthetic polymer selected from poly(lactic acid) (PGA) and / or poly (DL-lactide-Co-glycolide) (PLGA) and / or poly (DL-lactide-Co-caprolactone) (PCL), collagen-bonded synthetic polymers selected from Poly(3-hydroxybutyrate) (PHB)+++, poly(e-caprolactone) (PCL), poly-lactic acid (PLA), polyamide (PA), polylactic acid (PLA), polyglycolic acid (PGA), poly(L-lactic) (PLLA), PLGA, poly (anhydrides) (PA), polycarbonate (PC), hydroxy acids, polyortho-esters (POE), propyl fumarates (PPF), polysaccharides, polylactone (PL), polycaprolactones, polyamides, polyamino acids, polyacetals, polyphosphazen (PPZ), biodegradable polycyanoacrylates, biodegradable polyurethanes (PU), polypyrrole, polyanilines, polythiophene, polystyrene, polyester (PE), non-biodegradable polyurethanes, polyureas, polyethylene terephthalate (PET), poly (ethylene vinyl acetate), polypropylene, polymethacrylate, polyethylene, polycarbonates, polyethylene oxide, polyvinyl alcohol (PVA), spindle-tex (polytetrafluoroethylene), dacron (polyethylene terephthalate), polytetrafluoroethylene (PTFE), polyethylene glycol (PEG), and polyglycerol sebacate (PGS).

3. The method according to claim 1, characterized in that said support is a three-dimensional cross-linked polymer scaffold, preferably cross-linked collagen, which has a porosity of 20 to 200 µm, and which optionally comprises adhesion peptide molecules, preferably RGD peptide molecules, covalently bonded to the polymeric structure of the solid support.

4. The method according to claim 1, characterised in that said support is made of cross-linked collagen, which has a porosity of 20 to 200 µm.

5. The method according to claim 3 or 4, characterized in that said carrier comprises adhesion peptide molecules, in particular RGD peptide molecules, covalently bonded to the polymeric structure of the solid support.

6. The method according to any one of claims 1 to 5, characterised in that said biomaterial is kept out of freezing, at a temperature greater than or equal to 0°C, at a temperature greater than 0°C, at a temperature greater than 0°C and below 32°C, at a temperature greater than 0°C and below 10°C, at a temperature above 0°C and below 4°C; and is immediately available and functional.